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COORDINATION CHEMISTRY IN BIOLOGY AND MEDICINE 
 
 
 
PART I. 
Synthesis and Characterization of Novel Metal-Citrate Complexes and the Investigation of 
Metal-Citrate Transporters in Gram-Positive Bacteria 
 
Abstract. 
 
Syntheses of new barium, cadmium, calcium, cobalt, iron, lead, magnesium, manganese, nickel, 
and strontium citrate complexes have been attempted using different methods such as room 
temperature slow evaporation and hydrothermal reactions to create new metal-citrate complexes.  
Crystallizations were conducted under conditions varying metal and ligand concentrations, 
solution pH, temperature, solvents, and the presence of coligands.  All structures of crystals 
obtained were characterized by X-ray crystallography.  A novel lead-citrate complex was 
synthesized with a formula of (Na)[Pb5(C6H5O7)3(C6H6O7)(H2O)]  8H2O.  The structure is two-
dimensional with five unique lead sites and four unique citrate ligands.  Three of the citrates 
exhibit three deprotonated carboxylates and one of them exhibit only two deprotonated 
carboxylates.  To study the metal-citrate uptake in Escherichia coli and Lactococcus lactis, 
radioflux assays were performed using citrate that was radiolabeled with 14C. 
 
 
PART II. 
Synthesis and Characterization of Novel Bifunctional Single Amino Acid Chelates (SAAC) 
for Nuclear Imaging 
 
Abstract. 
 
99mTc(I) and Re(I) complexes can be used to visualize various diseases by linking the radioactive 
metal cation to biologically active molecules.  One type of bifunctional chelator is the single 
amino acid chelates (SAACs), which can be effectively coordinated to the {Re(CO)3}+ core 
through the chelating terminus.  The other terminus can be used to fuse the SAAC into a variety 
of different peptides or biomolecules.  Based on these strategies, syntheses of various SAAC 
ligands were investigated.  All structures of crystals obtained were characterized by X-ray 
crystallography.  A novel SAACQ-Zn complex was synthesized using an optimized direct 
reductive alkylation method.  Additionally, fluorescence and UV-Vis studies were done on 
Re(I)-SAAC compounds sent from collaborators. 
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PART I. SYNTHESIS AND CHARACTERIZATION OF NOVEL METAL-
CITRATE COMPLEXES AND THE INVESTIGATION OF METAL-
CITRATE TRANSPORTERS. 
 
Chapter 1. Introduction 
 
1.1 Transport Proteins 
 In the life cycle of a cell, large amounts of exchange are required to sustain normal 
function.  This exchange of biological molecules and disposal of waste products are critical for 
the growth, development, and activity of all living organisms.1  At the heart of this exchange lies 
the transport protein which ranges from simple systems that can transport single molecules or 
ions to larger, more complex systems.2,3  Figure 1.1 below shows the general scheme of the 
different types of transport that will be explained in greater detail below. 
The simplest type of transport is called passive transport, where an input of chemical 
energy is not required for the movement of molecules.4  In most cases, channel proteins mediate 
passive transport by forming hydrophilic pores across the lipid bilayer and only allow specific 
molecules to pass through when open.  There are four main types of passive transport; diffusion, 
facilitated diffusion, filtration, and osmosis. 
When energy is required for the transport of molecules, it is called active transport.  It 
involves the movement of molecules across a cell membrane from low to high concentration at 
the expense of metabolic energy.5  Carrier proteins mediate active transport by creating an 
opening by undergoing a conformational change upon binding of the molecule.4  Primary active 
transport6 and secondary active transport7 are the two types of active transport which will be 
described in greater detail below. 
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Figure 1.1 Schematic representation of active and passive transport.  The orange (left) 
protein represents passive transport, which transports molecules from high to low concentration 
without energy.  The brown (right) protein represents active transport, which transports 
molecules from low to high concentration with the input of an energy source. 
 
 1.1.1 Membrane Transport Proteins 
 Membrane transport proteins are responsible for the movement of ions,8 
macromolecules,9 and small molecules10 across a cellular membrane via primary and secondary 
active transport.  Figure 1.2 below shows the difference between the two types of active 
transport. 
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Figure 1.2 Schematic representation of primary and secondary active transport.  The yellow 
protein (right) represents primary active transport, which utilizes energy in the form of ATP to 
transport molecules from low to high concentration.  The orange protein (left) represents 
secondary active transport, which moves molecules across the membrane by pumping ions in or 
out of the cell. 
 
Primary active transport requires the input of energy to move molecules from an area of 
low concentration to an area of high concentration.11  The most common energy source used by 
cells is found in adenosine triphosphate (ATP), which is chemically harvested through 
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hydrolysis.12  When ATP undergoes an enzyme-catalyzed hydrolysis reaction, a phosphate (Pi) is 
removed and adenosine diphosphate (ADP) is formed.  This causes a conformational change in 
the transport protein and allows transport of molecules across the membrane.13,14  Primary active 
transport systems are considered energy-coupling devices since chemical and mechanical 
processes are linked together in order to achieve transport of molecules.  
 Secondary active transport achieves the same goal as primary active transport by using a 
different method.4  Rather than the direct coupling of ATP, secondary active transport relies on 
the electrochemical potential difference created by pumping ions in and out of the cell to move 
molecules across the membrane.15 
The two types of secondary active transport are known as symporter and antiporter which 
are classified by the direction of the movement of particles and ions in relation to each other.16  
Symport secondary active transport moves particles and ions across the cellular membrane in the 
same direction whereas antiport secondary active transport moves particles and ions across the 
cellular membrane in opposite directions.17 
 
 1.1.2 CitMHS Transport Proteins 
 One specific class of secondary active transport proteins is the CitMHS family (metal-
citrate H+ symport family).18,19  The first CitMHS member was discovered in Bacillus subtilis by 
Willecke et al. in 1973 and it was demonstrated that B. subtilis could transport citrate when 
complexed to Ba2+, Be2+, Ca2+, Co2+, Cu2+. Mg2+, Mn2+, Ni2+, Zn2+.20  In addition, Bergsma et al. 
concluded that CitMHS was a secondary transport protein.21 
Table 1.1 shows the confirmed CitMHS members and the metals transported for each 
transporter. 
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Bacteria Protein Metals transported 
Bacillus subtilis22 CitBs1 Co2+, Mg2+, Mn2+, Ni2+, Zn2+ 
Bacillus subtilis23 CitBs2 Ba2+, Ca2+, Sr2+ 
Streptococcus mutans24 CitSm Fe3+, Mn2+ 
Enterococcus faecalis25 CitEf Ca2+, Cd2+, Mn2+, Pb2+, Sr2+ 
Streptomyces coelicolor26 CitSc Ba2+, Ca2+, Fe3+, Mn2+, Pb2+ 
Corynebacterium glutamicum27 CitCg Ca2+, Sr2+ 
Kineococcus radiotolerans CitKr Ca2+ 
 
Table 1.1. Characterized CitMHS proteins and their respective metals transported.  Lolkema 
et al. characterized two CitMHS members in B. subtilis as well as in E. faecalis.  CitSm in S. 
mutans was characterized by Citkovitch et al.  Bott et al. characterized CitCg in C. glutamicum. 
Lastly, Doyle et al. characterized both CitSc and CitKr in S. coelicolor and K. radiotolerans, 
respectively. 
 
 A large number of known citrate transporters in bacteria belong to a specific class of 
secondary transport proteins known as the 2-hydroxycarboxylate transporter (2HCT) protein 
family.28  This class of proteins utilizes an electrochemical gradient with sodium or proton ions 
to drive the transport via a symport method.29  Figure 1.3 below shows the general scheme for 
metal-citrate transport. 
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Figure 1.3 Schematic representation for divalent metal-citrate complex symport with a 
proton.30 
 
 However, not all citrate transport proteins are symporters.  Table 1.2 shows three known 
transport proteins that are exceptions to the symport trend. 
 
Bacteria Protein In Out 
Escherichia coli CitT Citrate Succinate 
Klebsiella pneumoniae CitW Citrate Acetate 
Lactococcus lactis CitP Citrate Lactate 
 
Table 1.2 Three exceptions to the symport trend.  E. coli, K. pneumoniae, and L. lactis 
exhibit antiport behavior.  CitT,31 CitW,32 and CitP33,34 transport citrate into the cell and transport 
succinate, acetate, and lactate out of the cell, respectively.31-34 
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1.2 Citrate 
 1.2.1 Biology and Chemistry 
Citrate, a tricarboxylic acid naturally found in all living cells, is a ubiquitous bioligand 
used in nature as a carbon source, energy intermediate, mild chelating agent, solubilizing agent, 
and buffer.35-37  Under aerobic conditions, organisms consume citrate for metabolization through 
the tricarboxylic acid (TCA) cycle (or citric acid cycle or Krebs cycle).38  Under anaerobic 
conditions, citrate undergoes three different fermentation pathways producing lactate, acetate, 
and succinate.39  Figure 1.4 below shows the structure of citrate and Figure 1.5 shows the 
different species that can exist under various pH conditions. 
 
 
Figure 1.4 Structure of citrate.  Citrate consists of a six carbon backbone with three 
carboxylate groups and one hydroxyl group.  It has a formula of C6H5O73- under neutral pH 
conditions as shown in the image above.40 
 
Citrate has four ionizable groups, which consist of three carboxyl groups and one 
hydroxyl group where the pKa values of the carboxyl groups are unusually close (pK1 = 3.13, 
pK2 = 4.76, and pK3 = 6.40).  The pKa for the hydroxyl group is ~11+,41-46 although more recent 
studies have found the pKa of the hydroxyl group could be as high as ~14.47 
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Figure 1.5 Different species of citrate.  Depending on the pH, citrate can have five distinct 
ligand species using a formula of HxCitHy where x = 0-1 (hydroxyl proton) and y = 0-3 
(carboxylate proton).40 
 
 1.2.2 Metal-Citrate Complexes and Coordination 
 The chemistry of citrate is complex with a variety of different binding modes reported as 
a result of four different sites in which metals can bind (three carboxyl groups and one hydroxyl 
group).  Simple monocarboxylates can bind metals in various ways as shown in Figure 1.6 
below.48-50 
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Figure 1.6 Various binding modes of metals to simple monocarboxylates. 
 
 
Figure 1.7 Schematic of common bidentate coordination modes of a polyfunctional 
tricarboxylic acid ligand. 
 
Citrate coordination chemistry is complicated furthermore by the variety of chelating and 
bridging modes that are commonly observed due to numerous potential coordination sites 
available on the multifunctional ligand.  Figure 1.7 above shows the different binding modes 
(bidentate and tridentate), which are more complex than simple monocarboxylates.48-50 
	   10 
 The flexibility of the citrate ligand gives way to two different types of binding modes, 
denticity and nuclearity, which contribute to the structure of the ligand. 
Denticity refers to the number of donor groups in a single ligand that bind to a central 
atom.  Most metal-citrate complexes have been reported to exhibit a mono-, bi-, or tridentate 
mono-metal motif.  Ni(III),51 Ca(II),52 and Ga(III)53 have been shown to bind to citrate in a 
bidentate manner through the carboxylate donors while Ti(IV)54 and Al(III)55 have been shown 
to bind citrate involving the hydroxyl group in a bidentate fashion.  Tridentate complexes have 
been reported for Cu(II), Cr(III), Fe(III), Pb(II), and Cd(II) metals.56  Figure 1.8 below shows a 
uranium-citrate which is unique in that a binuclear bidentate structure was reported where 
alkoxide groups bridge the metal ions.57 
 
 
Figure 1.8 Structure of the binuclear and bidentate uranium-citrate.   
  
 In addition to mono-metal coordination motifs, citrate is capable of binding different 
metals by virtue of its coordinative flexibility.  Due to this trait, several hetero-metal complexes 
have been reported.  Some examples include Mn(II) binding along with Ca(II) and Na(I) in 
separate complexes.58  Sb(III) has been shown to bind citrate in the presence of other metals such 
as potassium, silver, sodium, cobalt, and lithium, resulting in di-metallic citrate complexes.59 
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 Nuclearity is defined as the number of central atoms joined in a single coordination 
complex by bridging ligands.  Figure 1.9 below shows examples of iron(III)-citrate and its ability 
to demonstrate structural variety by exhibiting mono-, bi-, and trinuclear species. 
 
 
Figure 1.9 Various nuclearities of Fe(III)-citrate.  (a) mononuclear [Fe(C6H4O)2]5-, (b) 
binuclear [Fe2(C6H5O7)2(H2O)2]2-, (c) trinuclear [Fe3O(C6H6O7)3]2-.60-64 
 
A simple mononuclear (di-citrate and tridentate) complex [Fe(C6H4O)2]5- with fully deprotonated 
ligands was prepared from an iron nitrate-citric acid solution (1:2 mol ratio) at pH 8.60  When 
equimolar quantities of ferric nitrate and sodium citrate are used, the binuclear species 
[Fe2(C6H5O7)2(H2O)2]2- is formed.61,62  This is also the same species found in a crystallographic 
study of the outer membrane transporter FecA from E. coli.61,63  Another binuclear species 
containing three bridging citrate ligands, [Fe2(Hcit)3]3- was also revealed.  A separate study of 
iron transport species in plant xylem sap from Solanum lycopersicum identified a tri-iron oxo-
cluster trinuclear complex, [Fe3O(C6H6O7)3]2-.64 
 Aside from the traditional mono-, bi-, and tridentate binding motifs, more complex 
structures involving tetranuclear ([Fe4(cit)4]8-),65 octanuclear 
	   12 
([Fe8(O)2(OH)2(cit)6(CH3CO2)2(imidazole)2]8-),66 and even nonanuclear ([Fe9O(cit)8(H2O)3]7-)67 
species exist.  It is interesting to note that Mn(II) is also capable of achieving a cubane or 
tetranuclear structure.68 
 
 1.2.3 Metal-Citrate Complexes and Speciation 
 While solid-state structures are helpful in identifying specific trends in binding modes, it 
is also important to understand from a biological standpoint, which species exist in solution.  
Potentiometric titration studies were conducted to measure the metal-citrate speciation.  The 
electrical gradient potential of the system can be measured through a range of pH values and the 
existing species can be calculated using the potential found.  Martell et al. has done work on 
finding the stability constants of various metal-citrate complexes.   Gustafsson developed a 
program, Visual MINTEQA2, which takes into account ionic strength, pH, and temperature, 
breaks down molecules and ions to a fundamental level and calculates which species exist along 
with the percentage. 
Table 1.3 shows the metal-citrate speciation calculation using Ca(II).  Since the focus of 
study for transport is metal-citrate complexes, it is crucial for 100% of the citrate to complex to 
the metal, or as close to 100% as possible.  These percentages are crucial for the radio flux 
assays performed in later chapters.  Table 1.4 shows the speciation for a range of metal-citrate 
complexes studied.  Most of the metal-citrate complex percentages are over 90% but due to the 
poor solubility of Fe3+, the concentration was greatly reduced.  As a result, the speciation 
percentage decreased to 80%. 
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Component % of Total Concentration Species 
Ca2+ 99.979 Ca2+ 
 0.021 Ca-Citrate- 
Citrate3- 0.705 Citrate3- 
 0.088 H-citrate2- 
 98.998 Ca-Citrate- 
 0.209 CaH-Citrate (aq) 
 
Table 1.3 Ca-Citrate speciation.  [Ca2+] was set to 401 mg/L and [Citrate3-] was set to 0.392 
mg/L.  pH was fixed to 7.0 and the ionic strength was allowed to fluctuate within the 
calculations. 
 
Metal [Metal] (mM) % Metal-Citrate 
Ba2+ 10 95.834 
Ca2+ 10 98.998 
Co2+ 1 99.687 
Cu2+ 0.01 99.348 
Fe3+ 0.075 80.543 
Mg2+ 1 97.184 
Mn2+ 1 98.431 
Ni2+ 1 99.857 
Pb2+ 1 99.044 
Sr2+ 1 92.245 
 
Table 1.4 Metal-citrate speciation.  The % metal-citrate values show the species used in 
experiments while fixed at pH 7.0.  [Ba2+] = 1373.3 mg/L, [Ca2+] = 401 mg/L, [Co2+] = 58.93 
mg/L, [Cu2+] = 0.6355 mg/L, [Fe3+] = 4.19 mg/L, [Mg2+] = 24.31 mg/L, [Ni2+] = 58.69 mg/L, 
[Pb2+] = 207.2 mg/L, [Sr2+] = 87.62 mg/L. 
 
1.3 Conclusion 
 The study of metal-citrate transport in bacteria includes factors as diverse coordination 
chemistry of metal-citrate complexes, bacterial preference for bidentate complexes with unbound 
hydroxyl groups (i.e. lead(II) citrate binds to the hydroxyl group preventing the citrate from 
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being metabolized),69 and the presence of citrate in soil.  Currently, much of the knowledge in 
terms of understanding the specifics of this transporter family remains unknown.  Amino acid 
residues that are crucial for binding and recognition, metal-citrate binding modes that could 
affect recognition, and the ability to determine which proteins transport which metal-citrate 
complexes, as well as the mechanism involved, have yet to be investigated. 
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Chapter 2. Metal-Citrate Transport and Protein Expression for CitBa and CitmrSa in 
Escherichia coli and Lactococcus lactis for Potential Antibody/Vaccines 
Against Anthrax and MRSA 
 
 
 
2.1 Introduction 
 
2.1.1 Metal-Citrate Transport  
 The acquisition of metals and carbon is very important to the growth of organisms, as 
their survival depends on the availability of these nutrients.1  Biologically, organisms can utilize 
citrate as both energy and carbon source while metal ions are necessary for many protein 
functions as they can facilitate or inhibit biological reactions.2   Some examples of metal 
dependent systems include manganese/calcium cluster for oxygen-evolving complexes (OEC), 
iron for hemoglobin, cobalt for vitamin B12, and molybdenum/iron cluster for nitrogenase.2  
Chemically, citrate can be used as a chelator and as a solubilizing agent3 while metals allow for 
redox chemistry to take place. 
Recent studies have demonstrated that metal-citrate complexes are transported in symport 
with protons.  While extensive research has been conducted regarding the transport of free 
uncomplexed citrate across cell membranes,4 there has been very little research performed 
regarding the transport of metal-bound, complexed citrate.5 
 
 2.1.2 Anthrax and Methicillin-Resistant Staphylococcus aureus (MRSA) 
 Staphylococcus aureus and Bacillus anthracis are both believed to have CitMHS 
members, pCitSa and pCitBa, respectively.6 
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In particular the methicillin-resistant Staphylococcus aureus (MRSA) is responsible for 
causing several types of infections in humans, most of which are difficult to treat.  Outbreaks are 
most commonly associated with poor hygiene practice in crowded and confined areas such as 
hospitals, prisons, military barracks, homeless shelters, locker rooms, and gyms.7,8  MRSA has a 
high rate of mortality due to its ability to cause septicemia which can ultimately lead to death.9-12 
B. anthracis is the cause of the deadly disease known as anthrax.  It can form extremely 
durable endospores (spores) that are capable of remaining dormant and surviving harsh 
conditions for as long as centuries.13  Coupled with the fact that it is easily produced in vitro, this 
makes it extremely well suited to be used as biological weapons.14-16  Once infected the bacteria 
attack the lymph nodes, where they will become activated and begin to multiply17, typically 
killing the host within a few days or weeks.18 
Currently, CitMHS members are found to exist only in prokaryotes.  This allows for the 
isolation and purification of these proteins as ideal candidates for antibody studies that could lead 
to better and more effective vaccines against anthrax and MRSA. 
 
2.2 [14C]-Citrate and Metal Transport Studies 
To begin the metal-transport studies, the complete genomic sequence for Staphylococcus 
aureus and Bacillus anthracis was studied and compared against the sequence of other bacteria 
that have known CitMHS members.  Once the region predicted to contain the CitMHS protein 
was located, primers were designed to build the genes, CitmrSa and CitBa, named after their 
respective hosts.  Due to the pathogenic nature of S. aureus and B. anthracis, both genes were 
cloned and expressed into L. lactis and E. coli using various shuttle vectors and plasmids. 
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Several different plasmids were used for a variety of reasons.  pNZ8149 is the native 
expression vector for L. lactis which allows for the CitmrSa gene to incorporate into the cell.  The 
pET25b(+) is a common plasmid to use with E. coli and the JWΔfec is the removal of the Fe3+-
citrate fec operon in E. coli.  pelB is a leader sequence that is fused with the N terminus of the 
desired protein.  This directs the protein into the periplasmic space where the sequence is cleaved 
by a signal peptidase.  Once the sequence is cleaved, the protein enters into the extracellular 
matrix.   Expression systems without the leader sequence (NLS = no leader sequence) were also 
constructed.  MISTIC (MIS) is a membrane fusion protein from Bacillus subtilis and serves to 
replace the pelB leader sequence as well as the native CitmrSa leader sequence.  The list below 
shows the different expression systems used for the radio flux assays. 
• pNZ8149_CitmrSa 
• pET25b(+)_CitmrSa 
• pET25b(+)_CitmrSa_pelB 
• pET25b(+)_CitmrSa_NLS 
• JWΔfec_pET25b(+)_pLEMO_CitmrSa 
• JWΔfec_pET25b(+)_pLEMO_CitmrSa_pelB 
• JWΔfec_pET25b(+)_pLEMO_CitmrSa_NLS 
• JWΔfec_pET25b(+)_pLEMO_CitBa 
• JWΔfec_pET25b(+)_pLEMO_MIS_CitBa 
 
Tables 2.1-2.7 below show some examples of different expression systems and growth 
conditions used for radio flux assays.  Depending on the expression system, NISIN, isopropyl β-
D-1-thiogalactopyranoside (IPTG), rhamnose, or a combination of the two was used to induce 
production of the protein. 
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OD600 Induction Time (hour) Induction Temperature (°C) NISIN (ng/mL) 
0.45 1 30 1 
0.45 4 30 1 
0.45 1 30 10 
0.45 4 30 10 
1.0 1 30 1 
1.0 4 30 1 
1.0 1 30 10 
1.0 4 30 10 
0.45 14 30 10 
 
Table 2.1 Growth conditions used for pNZ8149_CitmrSa, induced with NISIN at various 
times and concentrations. 
 
 
 
OD600 Induction Time (hr) Induction Temp (°C) Rhamnose (mM) IPTG (mM) 
0.45 1 30 0 0.5 
0.45 1 30 1 0.4 
0.45 1 30 2 0.4 
1.0 1 30 0 0.5 
1.0 1 30 1 0.4 
1.0 1 30 2 0.4 
0.45 4 30 0 0.5 
0.45 4 30 1 0.4 
0.45 4 30 2 0.4 
1.0 4 30 0 0.5 
1.0 4 30 1 0.4 
1.0 4 30 2 0.4 
 
Table 2.2 Growth conditions used for JWΔfec_pET25b(+)_pLEMO_CitmrSa_pelB at 30 °C, 
induced with L-rhamnose and IPTG at various times and concentrations. 
 
 
 
OD600 Induction Time (hr) Induction Temp (°C) Rhamnose (mM) IPTG (mM) 
1.0 8 30 1 0.5 
 
Table 2.3 Growth conditions used for pET25b(+)_CitmrSa_pelB at 30 °C, induced with L-
rhamnose and IPTG for 8 hours. 
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OD600 Induction Time (hour) Induction Temperature (°C) Rhamnose (mM) 
1.0 1 30 1.0 
 
Table 2.4 Growth conditions used for JWΔfec_pET25b(+)_pLEMO_MIS_CitBa at 30 °C, 
induced with L-rhamnose for 1 hour. 
 
 
 
OD600 Induction Time (hr) Induction Temp (°C) Rhamnose (mM) IPTG (mM) 
0.45 1 15 0 0.5 
0.45 1 15 1 0.4 
0.45 1 15 2 0.4 
1.0 1 15 0 0.5 
1.0 1 15 1 0.4 
1.0 1 15 2 0.4 
0.45 4 15 0 0.5 
0.45 4 15 1 0.4 
0.45 4 15 2 0.4 
1.0 4 15 0 0.5 
1.0 4 15 1 0.4 
1.0 4 15 2 0.4 
 
Table 2.5 Growth conditions used for JWΔfec_pET25b(+)_pLEMO_CitmrSa_pelB at 15 °C, 
induced with L-rhamnose and IPTG at various times and concentrations. 
 
 
 
OD600 Induction Time (hr) Induction Temp (°C) 
0.45 1 30 
0.45 4 30 
1.0 1 30 
1.0 4 30 
0.45 1 15 
0.45 4 15 
1.0 1 15 
1.0 4 15 
 
Table 2.6 Growth conditions used for JWΔfec_pET25b(+)_pLEMO_CitBa at 15°C and 30 
°C, induced at various times. 
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OD600 Induction Time (hour) Induction Temperature (°C) IPTG (mM) 
0.45 1 30 0.01 
0.45 1 30 0.1 
0.45 1 30 0.5 
0.45 1 30 1.0 
1.0 1 30 0.01 
1.0 1 30 0.1 
1.0 1 30 0.5 
1.0 1 30 1.0 
0.45 1 15 0.01 
0.45 1 15 0.1 
0.45 1 15 0.5 
0.45 1 15 1.0 
1.0 1 15 0.01 
1.0 1 15 0.1 
1.0 1 15 0.5 
1.0 1 15 1.0 
 
Table 2.7 Growth conditions used for JWΔfec_pET25b(+)_pLEMO_MIS_CitBa, induced 
with IPTG at various temperatures and concentrations 
 
 
 
The metals used for radio flux assays were selected based on which metal-citrates were 
known to be transported by other organisms.  Each metal tested was performed in triplicate and 
all cells were washed three times with 50 mM PIPES buffer, pretreated with Chelex-100. 
Figures 2.1-2.4 below are some examples of radio flux assays showing metal-citrate and 
free citrate uptake. 
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Figure 2.1 Radio flux assay results for JWΔfec_pET25b(+)_pLEMO_MIS_CitBa grown to 
OD600 = 1.0 and induced with  1.0 mM L-rhamnose for 1 hour at 30 °C. 
 
 
 
 
 
Figure 2.2 Radio flux assay results for pNZ8149_CitmrSa grown to OD600 = 0.45 and induced 
with 10 ng/mL NISIN for 4 hours at 30 °C. 
 
 
 
	   28 
 
Figure 2.3 Radio flux assay results for pET25b(+)_CitmrSa grown to OD600 = 1.0 and induced 
with 0.5 mM IPTG for 1 hour at 30 °C. 
 
 
 
 
 
Figure 2.4 Radio flux assay results for pET25b(+)_CitmrSa_pelB grown to OD600 = 1.0 and 
induced with 0.5 mM IPTG and 1.0 mM L-rhamnose for 8 hours at 30 °C. 
 
 
 
2.3 Protein Expression and Purification of pGEX-4T-3_CitBa_(284 and 369)-434_FXa 
  
 CitMHS members are a class of proteins whose structure is comprised of twelve alpha 
helices.19,20  Rather than build the full twelve helix structure (shown below in Figure 2.5), two 
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separate portions of the protein were built.  CitBa_284-434 makes up for four of the helices while 
CitBa_369-434 makes up for two of the helices.  The numbers 284-434 and 369-433 represent the 
amino acids from the full protein sequence.  These specifically selected regions were predicted to 
be critical in metal-citrate recognition and transport. 
 
 
Figure 2.5 Schematic representation of the complete twelve α-helix protein.  Each helix is 
represented in a different color. 
 
 All purifications were done by adding a glutathione S-transferase (GST) tag to each of the 
proteins and using fast protein liquid chromatography (FPLC).  To start, a cell only control was 
expressed to make sure nothing in the vector or cell bound to the GST column.   Figure 2.6 
below shows a typical trace from the FPLC.  There are no peaks shown after the blue line 
baseline, which indicates that nothing was bound to the GST column. 
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Figure 2.6 FPLC graph from the purification of the pGEX-4T-3 cell control. 
 
Now a GST only control must be done to ensure that GST can be expressed and purified.  
Figure 2.7 below shows the typical trace off the FPLC column.  There is a peak after the baseline 
(blue line) that indicates the GST was expressed. 
 
 
Figure 2.7 FPLC graph of the purification of GST only control. 
 The protein was then eluted off the column and run on gels that were coomassie stained 
and western blotted.  Figure 2.8 below shows the results of these gels. 
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Figure 2.8 Protein gel of GST only control.  The big, dark spot on the gel shows that GST 
was successfully purified using FPLC.   The GST protein has a mass of 26 kDa that matches 
perfectly against the markers to the left. 
 
 Once the controls were successfully completed, time course experiments were conducted 
to maximize protein production by optimizing induction concentrations.  Various concentrations 
of IPTG were used to induce protein production and the same procedure was followed as 
mentioned above for expression and purification.  Figures 2.9 and 2.10 below show protein gels 
and western blots for 2- and 4-helix expression and purification experiments. 
 
 
Figure 2.9 Protein gel (left) and western blot (right) of pGEX-4T-3_CitBa_369-434_FXa (2-
helix) fragment. 
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Figure 2.10 2x identical protein gels of pGEX-4T-3_CitBa_284-434_FXa (4-helix) fragment. 
 
 
2.4 Summary and Conclusions 
 It was demonstrated that none of the expression systems were successful in transporting 
metal-citrate complexes.  Each system was subject to an extensive amount of growth studies in 
hopes of finding the ideal conditions.  Unfortunately, gain of function studies for the CitMHS 
proteins showed no metal-citrate transport even though the cloning and expression of each 
system was successful.  Although the CitMHS proteins may have been expressed properly, it 
may not be fully functional because expression did not occur in its native host organism.  L. 
lactis and E. coli may have recognized the gene as a foreign entity and taken certain security 
measures to purge itself of the potential threat.  Different shuttle vectors/plasmids were used to 
compensate for that fact but may have inadvertently introduced additional complications.  Using 
these various methods to deceive the bacteria into accepting foreign genes seemed plausible in 
theory and specific precautions were taken to ensure success but ultimately failed. 
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 Figure 2.9 above shows the successful expression of the 2-helix protein fragment.  The 
expected size of the protein is 33.3 kDa, which matched up nicely against the ladder.  However, 
the purification after cleavage produced no protein.  Figure 2.10 above showed protein gels of 
the 4-helix fragment that have been coomassie stained.  The expected size of the protein is ~43 
kDa but no bands were visible in this range.  No bands appeared on the X-ray film after western 
blotting either.  The purification process of the final product was unsuccessful in both the 2- and 
4-helix fragments.  A possible explanation for this observation might be the expression of only 
GST or the protein was not behaving as expected during the purification and cleavage process.  
Successful protein function may require the full twelve helical structure rather than incomplete 
2-helix or 4-helix fragments.  This may result in the protein being unrecognized by the bacteria.   
 
2.5 Materials and Methods 
Broth and buffer materials were purchased from Becton Dickinson and Company (Franklin 
Lakes, NJ), VWR (Radnor, PA), Sigma-Aldrich (St. Louis, MO), J. T. Baker (Jackson, TN), or 
Merck (White House Station, NJ). 
Water used was distilled and deionized to 18.2 MΩ via Barnstead™ NANOpure® DIamond™. 
Chelex® 100 Resin was purchased from Bio-Rad (Hercules, CA). 
Metal-salts were of at least 99% purity and purchased from Sigma-Aldrich. 
DNA was isolated using Promega Wizard® Plus SV Miniprep kit or Omega E.Z.N.A.® Plasmid 
Mini kit. 
Primers were ordered from Integrated DNA Technologies (Coralville, IA). 
DNA was sequenced by the DNA Sequencing Core Facility or by Genewiz (South Plainfield, 
NJ). 
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2 log DNA ladder was purchased from New England Biolabs (Ipswich, MA). 
Protein markers (broad range, 2-212 kDa) were ordered from New England Biolabs. 
Kaleidoscope™ protein markers were purchased from Bio-Rad. 
All cells were incubated in a MaxQ™ 5000 Floor-Model Shakers or 4000 Benchtop Orbital 
Shakers from Thermo Scientific (Waltham, MA). 
Cell density was determined using a Varian Cary® 50 UV-Vis Spectrometer, measuring 
absorbance at 600 nm (OD600). 
pGEX-4T-3 and pET25b(+) vectors were purchased from Novagen (Darmstadt, Germany). 
[14C]-citric acid (250 µCi) was purchased from Sigma-Aldrich and PerkinElmer (Waltham, MA). 
All radiation counts were detected by a PerkinElmer Tri-Carb® 2900TR Liquid Scintillation 
Analyzer. 
Scintillation fluid and vials were purchased from Fisher Scientific (Hampton, NH). 
Western blots were performed on an Original iBlot® Gel Transfer Device by Invitrogen™ from 
Life Technologies (Grand Island, NY). 
Antibodies for western blots were purchased from Abcam (Cambridge, MA). 
Supersignal™ West Pico Chemiluminescent Substrate solution for western blot development 
was purchased from Thermo Scientific. 
Proteins were purified using a ÄKTAprime plus FPLC from General Electric (Schenectady, 
NY). 
Polymerase chain reactions (PCR) were carried out on a TC-312 Thermal Cycler by Techne™ 
(Staffordshire, United Kingdom). 
Cells were incubated in a MaxQ™ 4000 Incubator by Phoenix Scientific, Inc. (Rochester, NY). 
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Everything was used with permission from Dr. Robert P. Doyle in his laboratory at Syracuse 
University, Syracuse NY. 
 
 2.5.1 Media Recipes 
 Lysogeny Broth (LB) 
• 500 mL Schott bottle 
• 0.5% yeast extract (2.5 g) 
• 1% NaCl (5.0 g) 
• 1% tryptone (5.0 g) 
• dH2O until a final volume of 500 mL 
• Stir until completely dissolved 
• Autoclave at 121 °C for 20 minutes 
• Cool to ~55 °C 
• Add appropriate antibiotic (ampicillin or kanamycin) 
  
 G/L-M17 Media 
• 1000 mL Schott bottle 
• 0.5% pancreatic digest of casein (tryptone, 5.0 g) 
• 0.5% soy peptone (5.0 g) 
• 0.5% beef extract (5.0 g) 
• 0.25% yeast extract (2.5 g) 
• 0.05% ascorbic acid (0.5 g) 
• 0.025% MgSO4 (0.25 g) 
• 1% disodium-β-glycerophosphate (10 g) 
• dH2O until a final volume of 950 mL 
• Stir until completely dissolved 
• Autoclave at 121 °C for 15 minutes 
• Cool to ~55 °C 
• Add 50 mL filter sterilized 10% lactose or glucose solution (0.5% diluted) 
• Add appropriate antibiotic (chloramphenicol) 
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 G/L-SGM17B Media 
• M17 media 
• 0.5 M sucrose 
• 2.5% glycine 
• Autoclave at 121 °C for 15 minutes 
• Cool to ~55 °C 
• Add 50 mL filter sterilized 10% lactose or glucose solution (0.5% diluted) 
• Add appropriate antibiotic (chloramphenicol) 
 
 Super Optimal Broth (SOB) 
• 1000 mL Schott bottle 
• 2% typtone (20.0 g) 
• 0.5 yeast extract (5.0 g) 
• 8.56 mM NaCl (0.5 g) or 10 mM NaCl (0.584 g) 
• 2.5 mM KCl (0.186 g) 
• dH2O until final volume of 1000 mL 
• 10 mM MgCl2 (0.952 g) 
• 10 mM MgSO4 (2.467 g) 
• Stir until completely dissolved 
• Autoclave at 121 °C for 15 minutes 
• Add 20 mM glucose (3.603 g) 
 
 
 Super Optimal Broth with Catabolite Repression (SOC) 
• SOB media 
• Autoclave at 121 °C for 15 minutes 
• Add 20 mM glucose (3.603 g) 
 
 Plates 
• Add ~15 g/L agar to media 
• Autoclave at 121 °C for 15-20 minutes 
• Add appropriate carbon source (lactose or glucose) and antibiotic (ampicillin, kanamycin, 
or chloramphenicol) 
• Pour into sterile petri dishes 
• Cool until solidified 
• Store at 4 °C 
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2.5.2 Polymerase Chain Reactions (PCR) for Cloning 
 The template DNA primers were dissolved in 90 µL of elution buffer (EB).  A stock 
solution was made containing: 
• 128 µL dH2O 
• 5 µL forward primer 
• 5 µL reverse primer 
• 21 µL ThermoPol® buffer 
• 5 µL dNTPs 
• 2.1 µL Deep Vent™ polymerase 
• 5 µL DMSO. 
 
Table 2.8 below shows the different concentrations used from the stock solution for PCR. 
 
Tube # (ng/µL) Stock used (µL) Template DNA (µL) dH2O (µL) Total (µL) 
5 40 1 9 50 
10 40 2 8 50 
25 40 5 5 50 
50 40 10 0 50 
 
Table 2.8 PCR setup for gene amplification.  Template DNA stock solution was set to 50 
ng/µL. 
 
PCR tubes were placed into the thermocycling chamber and set for the following parameters: 
• 35 cycles 
• 95 °C as the denaturing temperature for 1 minute 
• [(Tmf + Tmr)/2] – 5 °C as the annealing temperature (where Tm1 and Tm2 represent the 
melting temperatures for the forward and reverse primers, respectively, for 1 minute 
• 74 °C as the annealing temperature for [(number of base pairs)/1000 + 0.25 min] 
 Following completion of gene amplification, the products were run down a 1% agarose 
gel (70 V, 90 minutes).  The DNA was extracted and double digested with their respective 
enzymes.  The double digested DNA was run down another 1% agarose gel under the same 
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conditions and extracted, which was saved for ligation.  Figures 2.11-2.12 below show some 
examples of successful PCR amplifications. 
 Double digest conditions are as follows: 
• 14 µL of DNA 
• 2 µL NBuffer # 
• 2 µL 10x BSA 
• 1 µL restriction enzyme I 
• 1 µL restriction enzyme II 
• Incubated at 37 °C for 1 hour 
 
 
Figure 2.11 1% agarose gel image captured of successful PCR of CitBa_369-434-FXa (196 
bp).  The gene size matched against the markers on the right. 
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Figure 2.12 1% agarose gel image captured of successful PCR of CitmrSa (1374 bp).  The gene 
size matched against the markers on the right. 
 
 2.5.3 Ligation of Gene into Vector 
 The vector being used was triple digested using the following conditions: 
• 13 µL of vector 
• 2 µL NEBuffer # 
• 2 µL 10x BSA 
• 1 µL restriction enzyme I 
• 1 µL restriction enzyme II 
• 1 µL CIP 
• Incubated at 37 °C for 1 hour 
 The total volume for both the double digest and triple digest was set to 20 µL.  Once the 
gene DNA and vector were double and triple digested, the concentrations were made to be 
identical by dilution using elution buffer.  Table 2.9 below shows the different concentrations 
used for ligation attempts.  Each ligation was held at 4 °C for 24 hours or 16 °C for a minimum 
of three hours. 
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Ratio 
(Gene:Vector) 
Gene 
(µL) 
Vector 
(µL) 
T4 DNA Ligase Reaction 
Buffer (µL) 
T4 DNA 
Ligase (µL) 
Total 
(µL) 
1:1 8.5 8.5 2 1 20 
3:1 12.75 4.25 2 1 20 
5:1 14.16 2.83 2 1 20 
10:1 15.45 1.55 2 1 20 
 
Table 2.9 Gene and vector ratios for ligations with concentrations determined by use of a 
nanodrop. 
 
 Figures 2.13-2.16 below show some examples of successful double digests of genes and 
triple digests of vectors. 
 
 
Figure 2.13 1% agarose gel image captured of the double digested gene CitBa_369-434_FXa.  
The size of the gene (196 bp) matched against the markers on the right. 
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Figure 2.14 1% agarose gel images captured of the triple digested vector pGEX-4T-3.  The 
size of the vector (4900 bp) matched against the markers on the left and right. 
 
 
Figure 2.15 1% agarose gel images captured of the triple digested vector pNZ8149.  The size 
of the vector (2548 bp) matched against the markers on the right. 
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Figure 2.16 1% agarose gel images captured of the double digested gene CitmrSa.  The size of 
the gene (1374 bp) matched against the markers on the right. 
 
 After the ligation was complete, a diagnostic digest was performed to ensure the success 
of the ligation.  Figures 2.17-2.21 below show some examples of successfully ligated systems 
 
 
Figure 2.17 1% agarose gel image captured of the successful ligation of the pNZ8149_CitmrSa 
construct.  The diagnostic digest showed the successful ligation of the gene (1374 bp) and vector 
(2548 bp). 
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Figure 2.18 1% agarose gel image captured of the successful ligation of the 
pET25b(+)_CitmrSa construct.  The diagnostic digest showed the successful ligation of the gene 
(1374 bp) and vector (5547 bp). 
 
 
Figure 2.19 1% agarose gel image captured of the successful ligation of the 
pET25b(+)_pLEMO_CitmrSa construct.  The diagnostic digest showed the successful 
transformation of the final system.  The pLEMO was single cut with XbaI and shown on right 
two lanes of the gel.  pET25b(+)_CitmrSa was double digested with XbaI and XhoI and the left 
two lanes show the double digested pET25b(+)_CitmrSa cut and separated on the gel.  The right 
two lanes also show the intact pET25b(+)_CitmrSa system because no restriction enzyme was 
added to cut it. 
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Figure 2.20 1% agarose gel image captured of the successful ligation of the pGEX-4T-
3_CitBa_369-434_FXa construct.  The diagnostic digest showed the successful ligation of the 
gene (196 bp) and vector (4900 bp). 
 
 
Figure 2.21 1% agarose gel image captured of the successful ligation of the pGEX-4T-
3_CitBa_284-434_FXa construct.  The diagnostic digest showed the successful ligation of the 
gene (450 bp) and vector (4900 bp). 
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 2.5.4 Chemical Transformations 
 Cells were made chemically competent by using a fresh colony or cell stock and growing 
them in their respective media, temperature, and RPM overnight.  The cells were then inoculated 
into 50 mL culture flasks until the OD600 reached 0.4 to 0.6.  Once the appropriate density was 
reached, the cells were centrifuged at 5000 G at 4 °C for 5 minutes.  Afterwards, the media was 
decanted and the cells were resuspended in 12.5 mL of a 100 mM MgCl2 solution and incubated 
on ice for 5 minutes.  The centrifuge step was performed again at 4000 G at 4 °C for 5 minutes.  
This time the solution was decanted and the cells were resuspended in 12.5 mL of a 100 mM 
CaCl2 solution and allowed to incubate on ice for 20 minutes.  A final centrifuge step was 
performed at 4000 G at 4 °C for 5 minutes, solution was decanted, and cells were resuspended in 
1.25 mL of a 100 mM CaCl2 + 15% glycerol solution.  The cells were then separated into 200 µL 
aliquots and stored in a freezer at -80 °C. 
 The chemically competent cells were added to the gene or vector DNA and incubated on 
ice for 30 minutes followed by a heat shock in a 43 °C water bath for 45 seconds.  The exposed 
mixture was incubated on ice for 2 minutes and super optimal broth with catabolite repression 
(SOC) was added.  This final mixture was incubated at the appropriate temperature for 1 hour 
and streaked onto plates for growth. 
 
 2.5.5 Electrical Transformations 
 Cells were made electrically competent by using a fresh colony or cell stock and growing 
it in its respective media, temperature, and RPM overnight.  The cells were then inoculated into 
50 mL culture flasks until the OD600 reached 0.2.  Once the appropriate density was reached, the 
cells were centrifuged at 6000 G at 4 °C for 20 minutes.  Afterwards, the media was decanted 
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and the cells were resuspended in 50 mL of a 0.5 M sucrose + 10% glycerol solution.  The 
centrifuge step was performed again at 8000 G at 4 °C for 20 minutes and the solution.  This 
time the solution was decanted and the cells were resuspended in 25 mL of a 0.5 M sucrose + 
10% glycerol + 50 mM EDTA solution and allowed to incubate on ice for 25 minutes.  Another 
centrifuge step was performed at 8000 G at 4 °C for 5 minutes and the cells were resuspended in 
12.5 mL of a 0.5 M sucrose + 10% glycerol solution.  A final centrifuge step was performed at 
8000 G at 4 °C for 20 minutes and the cells were resuspended in 500 µL of a 0.5 M sucrose + 
10% glycerol solution.  The cells were then separated into 40 µL aliquots and stored in a freezer 
at -80 °C. 
 The electrically competent cells were added to the gene or vector DNA and pulse 
shocked in a electroporator at 2000 V for 5 ms.  The exposed mixture was incubated on ice for 2 
minutes and super optimal broth with catabolite repression (SOC) was added along with 520 mM 
of a CaCl2 solution.  This final mixture was incubated at the appropriate temperature for 2 hour 
and streaked onto plates for growth. 
 
 2.5.6 Protein Purification 
 Colonies were picked and incubated in 5 mL culture tubes with LB media at 37 °C, 350 
RPM, overnight.  The cells were inoculated into 50 mL flasks and grown to an OD600 = 0.4.  
Various concentrations of IPTG was added to induce protein production and allowed to incubate 
for various times at 30 °C, 250 RPM.  The cells were then centrifuged at 4000 RPM at 4 °C for 
10 minutes.  Afterwards, the media was decanted and the cells were resuspended in Buffer A 
(1.8 mM K2HPO4, 2.7 mM KCl, 140 mM NaCl, 10 mM NaH2PO4, pH 7.3).  The membrane of 
the cell was broken and lysed by sonication using 10 x 2 second intervals, five times.  Once the 
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cells were lysed, the cell matter was centrifuged at 8500 G at 4 °C for 20 minutes.  The 
supernatant containing the protein was filtered and loaded onto the fast protein liquid 
chromatography (FPLC) at 4 °C.  Using Buffer B (10 mM reduced glutathione, 50 mM tris-HCl, 
pH 8.0), the protein was eluted off the column and fractions were collected.  The samples were 
precipitated using trichloroacetic acid (TCA) and run on two identical 12% SDS-PAGE gels.  
One gel was stained with coomassie and the other was used for western blotting using an anti-
GST antibody. 
  
 2.5.7 Western Blotting 
 The second gel was transferred onto a nitrocellulose membrane via an iBlot machine.  
This membrane was blocked with a 5% nonfat milk solution in TBST and stored at 4 °C for 1 
hour on a rocker followed by the addition of the anti-GST antibody in a 1:7000 ratio and 
incubated overnight at 4 °C.  The milk solution was subsequently discarded and the membrane 
was washed with 15 mL of a TBST solution for 15 minutes.  A total of eight washes were 
performed to ensure the milk solution was completely washed off.  The membrane was then 
transferred onto an X-ray cassette and the chemiluminescent solution was applied.  An X-ray 
film that was placed over the membrane was developed in a developing solution and washed in a 
fixing solution.  The film was left to dry and the resulting bands became visible. 
  
 2.5.8 14C Radio Flux Assays 
 To prepare cells for radio flux assays, a colony was picked, grown, and inoculated under 
appropriate conditions.  The cells were centrifuged at 8,500 G at 4 °C for 10 minutes.  The media 
was decanted and the cells were resuspended in 10 mL of a 50 mM PIPES solution pre-treated 
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with Chelex® 100 Resin adjusted to pH 7.0.  This wash step was performed two more times and 
the resuspended cells were stored on ice. 
 [1,5 14C]-citrate (the first and fifth carbon in the citrate molecule was replaced with the 
radioactive isotope, 14C) was used for the free-citrate control and for the complexing of metals in 
the radio flux assays.  Metal-citrate complexes were pre-complexed using 14C-citrate and the 
metal-chloride being investigated.  The concentrations are listed in Tables 1.3 and 1.4 in Chapter 
1.2.3. 
 Figure 2.22 below shows the set up for each radio flux assay.  100 µL of the resuspended 
cell solution was added to sixteen 2 mL microcentrifuge tubes.  5 µL of 14C-citrate was added to 
tubes 1-4 for a final concentration of 4.4 µM.  10 µL of the 14C-metal-citrate complex was added 
to tubes 5-16 for a final concentration of 4.4 µM.  Each solution was added as quickly as possible 
while maintaining accuracy to ensure accurate results due to the time sensitive nature of the 
experiments. 
 Once all cells and solutions were added, the samples were shaken at ~60 RPM and the 
timer begun.  When the timer hit ~52 seconds, the shaker was paused and 970 µL of chilled 0.1 
M LiCl solution was added into each tube across the ‘1-minute time point’ row to stop the metal-
citrate uptake, followed by an additional 970 µL into each tube for a total of 1940 µL.  The tubes 
were then removed, placed on ice, and the shaker started again.  This procedure was repeated for 
the 2, 3, and 5-minute time points. 
 A porcelain filter crucible was set on top of a Büchner flask attached to a water aspirator 
for vacuum filtration.  With a pair of tweezers, a 2.1 cm filter was placed in the crucible and 
rinsed with a small amount of chilled 0.1 M LiCl.  The samples that were placed on ice were 
carefully pipetted onto the wet filter ensuring the cells did not reach the edge of the filter, making 
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sure all cells were loaded on the filter paper.  The filter containing the cells was washed using 1 
mL of the same chilled 0.1 M LiCl three times, removed and placed into scintillation vials 
containing 5 mL of scintillation fluid.  Lastly, the vials were placed in a radiation transport 
container and taken to the Environmental Health and Safety Office (EHO) at Syracuse 
University for radiation count detection using the Liquid Scintillation Analyzer. 
 
 
Figure 2.22 Schematic representation of radio flux assays.  MC (white) – metal-citrate 
complex.  FC (grey) – free-citrate control.  Each row represents a different time point ranging 
from 1 to 5 minutes.  The larger number represents the order in which each sample was added. 
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Chapter 3. Novel Lead(II)-Citrate Complex 
Portions of this chapter were published in: 
Chu, C.; Darling, K.; Netusil, R.; Doyle, R. P.; Zubieta, J.  Synthesis and structure of a lead(II)-
citrate: {Na(H2O)3}[Pb5(C6H5O7)3(C6H6O7)(H2O)3]9.5H2O.  Inorganica Chima Acta, 2011, 
378, 186-193. 
 
3.1 Introduction 
 While the fundamental chemistry of specific metal-citrates such as the iron-citrate system 
has been studied extensively, the chemistries of other metal cations of significance such as Ba2+, 
Sr2+, and Pb2+ are less developed.1,2  These metal cations are significant because they exhibit 
uptake of the complex, even if it is weak compared to the background citrate uptake.3,4  Although 
the speciation and structural chemistry for the cadmium-citrate system have been thoroughly 
investigated,5 not much has been explored about the lead-citrate or strontium-citrate chemistry.  
The lead-citrate structural chemistry only includes a two-dimensional6 and three-dimensional7 
structure, while even less is known about the strontium-citrate system, with only a single 
polymeric structure reported to date.8  These structural results may simply be due to 
crystallization requirements and may not have any biological relevance, and the solution 
speciation of these cations with citrate and analogs such as isocitrate and fluorocitrate has still 
yet to be adequately established.9-11 
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3.2 Structure of {Na(H2O)3}[Pb5(C6H5O7)3(C6H6O7)(H2O)3]9.5H2O 
 
Crystallographic Data 
Empirical formula C24H52O43.5NaPb5 
Formula weight (g/mol) 2095.6 
Crystal system Triclinic 
Space Group  
a (Å) 11.348(1) 
b (Å) 13.210(1) 
c (Å) 16.480(2) 
α (°) 73.889(2) 
β (°) 88.852(2) 
γ (°) 73.087(4) 
V (Å3) 2265.8(4) 
Z 2 
 
Table 3.1 Crystallographic data for the structure of 
{Na(H2O)3}[Pb5(C6H5O7)3(C6H6O7)(H2O)3]9.5H2O (Pb5cit). 
 
Table 3.1 above summarizes the crystallographic data for the structure of 
{Na(H2O)3}[Pb5(C6H5O7)3(C6H6O7)(H2O)3]9.5H2O (Pb5cit).  The structure is two-dimensional 
with chains of alternating {Pb(1)2Pb(2)2} and {Pb(3)2Pb(4)2} tetranuclear clusters running 
parallel to the crystallographic a axis, linked through {Pb(5)2} binuclear units, as shown in 
Figures 3.1 and 3.2. 
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Figure 3.1 (a) Ball and stick representation of the structure 
{Na(H2O)3}[Pb5(C6H5O7)3(C6H6O7)(H2O)3]9.5H2O in the bc plane, showing two neighboring 
layers; hydrogen atoms, sodium cations, and water molecules of crystallization have been 
omitted for clarity.  (b) mixed polyhedral and ball and stick view; showing the locations of the 
sodium cations and coordinated water molecules.  Color scheme: lead – dark grey (a) spheres, 
(b) polyhedral; sodium – yellow spheres; oxygen – red spheres; carbon – black spheres.  Image 
was taken with permission from Chu et al.  Inorganica Chimica Acta, 2011, 378, 186-193.12 
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Figure 3.2 Polyhedral view of the linking of lead polyhedral in a simple layer in the ac plane.  
The lead sites have been color-coded for ease of identification.  Pb(1) sites – orange; Pb(2) sites 
– yellow; Pb(3) sites – green; Pb(4) sites – blue; Pb(5) sites – grey.  Image was taken with 
permission from Chu et al.  Inorganica Chimica Acta, 2011, 378, 186-193.12 
 
 Two previously reported lead citrate structures, [Pb(C6H6O7)]nH2O and 
[Pb6(H2O)2(C6H5O7)4]3H2O, display hydroxyl groups that are protonated along with distinct 
coordination modes of each citrate that link three to seven lead sites.  The two-dimensional 
[Pb(C6H6O7)]nH2O has citrate ligands that exhibit protonated carboxyl groups similar to the 
lead(II)-citrate of Pb5cit.  The three-dimensional [Pb6(H2O)2(C6H5O7)4]3H2O has two distinct 
citrate environments, both bridging five lead sites.  One of the citrates acts as a tridentate chelate 
to a single lead site.  Additionally, the hydroxyl group chelates to a lead center in all three of the 
citrate environments by forming a five-membered {Pb-O=C-C-O-} chelate ring.  Figures 3.3 and 
3.4 below summarize the citrate coordination environments for the two-dimensional and three-
dimensional structures, respectively. 
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Figure 3.3 Citrate coordination environment of the two-dimensional structure, 
[Pb(C6H6O7)]nH2O. 
 
 
Figure 3.4 Citrate coordination environment of the three-dimensional structure, 
[Pb6(H2O)2(C6H5O7)4]3H2O. 
 
 There are four unique citrate environments in the lead(II)-citrate structure of Pb5cit in 
which three of them are triply deprotonated and one is doubly deprotonated.  This refers to the 
carboxyl groups, as the hydroxyl groups in each distinct citrate environment are always 
protonated, similar to the two previously reported structures.  Each distinct citrate ligand binds 
three, five, seven, and again seven lead sites.  Three of the citrate ligands bind to a single lead 
center in a tridentate fashion which includes participation from the hydroxyl group.  The 
hydroxyl group participates in the tridentate geometry for all three instances, including the 
tridentate chelation mode of [Pb6(H2O)2(C6H5O7)4]3H2O.  Figure 3.5 summarizes the citrate 
coordination environment for the novel two-dimensional structure of Pb5cit. 
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Figure 3.5 Citrate coordination environment of the two-dimensional structure, 
{Na(H2O)3}[Pb5(C6H5O7)3(C6H6O7)(H2O)3]9.5H2O. 
 
Lead(II) compounds can adopt a wide scope of coordination numbers ranging from two 
to twelve.13  This large variety of configurations is reflected in the stereochemical activity of the 
lone pair of electrons as a result of an antibonding lead 6s-ligand np interaction that results in 
structural distortions to minimize the unfavorable interactions.14-15  Lead(II) complexes can be 
placed into one of two categories: hemidirected, where the electron distribution around the metal 
ion creates apparent gaps in the coordination sphere and homodirected, where the electronic 
distribution and consequently the coordination sphere are symmetric.16  Table 3.2 below shows 
the short lead(II)-oxygen bond distances that range from 2.35 – 2.79 Å and the longer bond 
distances of 2.81 – 3.20 Å. 
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Bond Lengths (Å) 
Pb(1) – O(x) Pb(2) – O(x) Pb(3) – O(x) Pb(4) – O(x) Pb(5) – O(x) 
O(08) 2.399(6) O(11) 2.552(6) O(22) 2.484(7) O(18) 2.557(7) O(13) 2.455(6) 
O(06) 2.521(6) O(15) 2.577(5) O(04) 2.547(6) O(05) 2.579(6) O(31) 2.515(6) 
O(01) 2.553(5) O(10) 2.610(6) O(07) 2.565(6) O(28) 2.717(6) O(21) 2.545(6) 
O(02) 2.625(6) O(07) 2.611(5) O(23) 2.595(6) O(23) 2.718(6) O(05) 2.631(6) 
O(29) 2.677(7) O(08) 2.641(6) O(27) 2.763(6) O(27) 2.723(7) O(17) 2.761(6) 
O(07) 2.842(6) O(30) 2.749(7) O(03) 2.840(6) O(20) 2.725(7) O(19) 2.805(6) 
O(16) 2.993(6) O(01) 2.797(6) O(28) 2.903(6) O(04) 2.752(5) O(19) 2.828(6) 
O(22) 3.055(6) O(06) 2.844(5) O(21) 2.933(7) O(19) 2.778(5) O(14) 2.851(6) 
 O(16) 2.948(6) O(11) 3.321(6) O(23) 2.852(6)  
 
Table 3.2 Selected bond lengths (Å) for 
{Na(H2O)3}[Pb5(C6H5O7)3(C6H6O7)(H2O)3]9.5H2O. 
 
Pb(1) has four carboxylate oxygens and a water molecule in the proximal locations with 
distances in the 2.309(6) – 2.677(6) Å and four carboxylate near neighbors in distal locations 
with distances 2.842(5) and 3.055(5) Å.  The coordination number may be represented as ‘5+4’. 
Pb(2) has six proximal ligands (four carboxylate oxygen donors, one hydroxyl, and an 
aqua ligand) in the 2.522(6) – 2.749(6) Å range and four distal contacts to carboxylate oxygen 
donors in the 2.797(5) – 2.948(5) Å range to give a coordination number of ‘6+4’. 
Pb(3)  has five proximal sites occupied by carboxylate donors at distances of 2.484(6) – 
2.763(6) Å and hydroxyl and carboxylate nearest neighbors in the range 2.840(5) – 2.980(5) Å.  
It exhibits a ‘5+4’ coordination similar to that of Pb(1). 
Pb(4) exhibits a ‘7+3’ coordination with seven carboxylate donors in the 2.557(5) – 
2.752(6) Å range and three carboxylate near neighbors between 2.778(6) – 2.852(5) Å. 
Pb(5) displays a ‘5+3’ coordination with the proximal positions occupied by four 
carboxylate and one hydroxyl donors with distances 2.455(6) – 2.761(6) Å range and three 
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carboxylate nearest neighbors at 2.805(5) – 2.881(5) Å.  Figure 3.6 summarizes each distinct 
lead environment. 
 
 
Figure 3.6 Ball and stick representations of the coordination spheres of the lead atoms.  The 
proximal oxygen donors are shown as filled grey spheres with solid bonds and the distal oxygen 
atoms are illustrated as open circles with dashed bonds.  Image was taken with permission from 
Chu et al.  Inorganica Chimica Acta, 2011, 378, 186-193.12 
 
3.3 Summary and Conclusions 
 The complex two-dimensional structure of Pb5cit consists of interconnected chains of 
{PbOn} polyhedral and citrate units.  The charge compensation provided by the sodium cation 
	   60 
and bonds to the pendant carboxyl group of the (C6H6O7)2- is essential for the crystallization of 
the structure. 
The coordination of the hydroxyl group plays an important role in the biology of metal 
citrate uptake by distinguishing between two binding motifs, bidentate and tridentate, which is 
relevant to the binding of citrate to M2+ cations.4  One binding motif that has been found in 
bidentate complexes utilizes two carboxyl groups, and has been reported for Ni2+ and Ca2+.  
Another bidentate method involves the hydroxyl group, which has been reported for Ti2+.  The 
second binding motif is through a tridentate one, for which complexes of Cu2+, Fe2+, Cd2+, and 
Pb2+ have been reported.  Pseudomonas fluorescens has been studied for its ability to metabolize 
metal-citrate complexes and the results show that tridentate complexes were not metabolized, 
while bidentate Ni2+ and Ca2+ complexes were metabolized.17  This leads to the conclusion that 
the hydroxyl group needs to be uncoordinated so that aconitase can recognize the citrate. 
Aconitase is an enzyme that functions to dehydrate and rehydrate citrate to form 
isocitrate via a cis-aconitate intermediate.18-20  An iron-sulfur cluster is used by aconitase to 
catalyze the isomerization of citrate to isocitrate.  In its inactive form, [Fe3-S4]+, each iron is 
bound to a cysteine residue.  To become active, a fourth iron molecule enters the simple cubane 
structure, creating a [Fe4S4]2+ cluster. The addition of the fourth iron molecule does not 
significantly change the conformation of the protein.  Once activated, the 4th iron binds to the 
hydroxyl group on the citrate while the catalytic residue His-101 protonates the hydroxyl group.  
Ser-642 allows the formation of a double bond forming the cis-aconitate intermediate.  The 
intermediate is then rotated 180°, referred to as a ‘flip’ and isocitrate is formed.18-28  Figure 3.7 
below shows the reaction mechanism for the conversion of citrate to isocitrate. 
 
	   61 
 
Figure 3.7 Aconitate mechanism for the formation of isocitrate from citrate. 
 
3.4 Methods and Materials (Chemistry) 
All chemicals were purchased from Sigma-Aldrich and used without further purification. 
All reagents were weighed in air and the reactions were conducted under an atmosphere of air, 
unless otherwise noted. 
All hydrothermal reactions were carried out in 23 mL polytetrafluoroethylene (PFTE) lined 
hydrothermal synthesis autoclave reactors. 
Water was distilled above 3.0 MΩ in-house using a Barnstead™ Model 525 Biopure Distilled 
Water Center from Thermo Scientific. 
pH of the reactions were measured using Hydrion™ pH sticks. 
Crystallographic data was collected with Bruker KAPPA APEX DUO diffractometer with an 
APEX II CCD detector. 
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 3.4.1 Metal-Citrates 
 Table 3.3 below shows the four combinations of various metal and citrate starting 
materials that were used in the syntheses of the following metal-citrate complexes. 
 
 Metal Ligand 
A “Metal” chloride Sodium citrate 
B “Metal” chloride Citric acid 
C “Metal” chloride Sodium citrate 
D “Metal” chloride Citric acid 
 
Table 3.3 Combinations of metal and citrate starting materials investigated in the synthesis 
of metal-citrate complexes. 
 
Strontium-Citrate 
 Each reaction was conducted in H2O (10 mL) as well as a H2O/DMF mixture (10 mL).  
Hydrochloric acid (HCl) was added in slow-addition (drop-wise) to the cloudy solutions 
containing sodium citrate until the solutions were clear.  Heat (60 °C) was applied to all solutions 
to increase reactivity and solubility.  Tables 3.4a-3.4d below shows all the combinations of 
starting materials and ratios used for each reaction.  All strontium-citrate solutions were colorless 
and allowed to undergo slow evaporation (vials were sealed with parafilm and a syringe needle 
was inserted) for crystal growth. 
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A 
Ratio Metal Ligand 
Metal Ligand Strontium chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
100 1 4.572 17.176 0.05 0.172 
80 1 3.658 13.741 0.05 0.172 
50 1 2.286 8.588 0.05 0.172 
20 1 0.914 3.435 0.05 0.172 
10 1 0.457 1.718 0.05 0.172 
9 1 0.412 1.546 0.05 0.172 
8 1 0.366 1.374 0.05 0.172 
7 1 0.320 1.202 0.05 0.172 
6 1 0.274 1.031 0.05 0.172 
5 1 0.457 1.718 0.1 0.344 
4 1 0.366 1.374 0.1 0.344 
3 1 0.274 1.031 0.1 0.344 
2 1 0.183 0.687 0.1 0.344 
1 1 0.1 0.376 0.109 0.376 
1 2 0.1 0.376 0.219 0.751 
1 3 0.1 0.376 0.328 1.127 
1 4 0.1 0.376 0.437 1.503 
1 5 0.1 0.376 0.547 1.878 
1 6 0.05 0.188 0.328 1.127 
1 7 0.05 0.188 0.383 1.315 
1 8 0.05 0.188 0.437 1.503 
1 9 0.05 0.188 0.492 1.690 
1 10 0.05 0.188 0.547 1.878 
1 20 0.05 0.188 1.094 3.757 
1 50 0.05 0.188 2.734 9.391 
1 80 0.05 0.188 4.374 15.026 
1 100 0.05 0.188 5.468 18.783 
 
Table 3.4a Strontium chloride and sodium citrate starting materials along with the molar 
ratios used in each reaction. 
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B 
Ratio Metal Ligand 
Metal Ligand Strontium chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
100 1 6.334 23.794 0.05 0.238 
80 1 5.067 19.035 0.05 0.238 
50 1 3.167 11.897 0.05 0.238 
20 1 1.267 4.759 0.05 0.238 
10 1 0.633 2.379 0.05 0.238 
9 1 0.570 2.141 0.05 0.238 
8 1 0.507 1.903 0.05 0.238 
7 1 0.443 1.666 0.05 0.238 
6 1 0.380 1.428 0.05 0.238 
5 1 0.633 2.379 0.1 0.476 
4 1 0.507 1.903 0.1 0.476 
3 1 0.380 1.428 0.1 0.476 
2 1 0.253 0.952 0.1 0.476 
1 1 0.127 0.477 0.100 0.477 
1 2 0.127 0.477 0.200 0.953 
1 3 0.127 0.477 0.301 1.430 
1 4 0.127 0.477 0.401 1.907 
1 5 0.127 0.477 0.501 2.384 
1 6 0.063 0.238 0.301 1.430 
1 7 0.063 0.238 0.351 1.668 
1 8 0.063 0.238 0.401 1.907 
1 9 0.063 0.238 0.451 2.145 
1 10 0.063 0.238 0.501 2.384 
1 20 0.064 0.239 1.003 4.771 
1 50 0.064 0.239 2.506 11.927 
1 80 0.064 0.239 4.010 19.083 
1 100 0.064 0.239 5.013 23.854 
 
Table 3.4b Strontium chloride and citric acid starting materials along with the molar ratios 
used in each reaction. 
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C 
Ratio Metal Ligand 
Metal Ligand Strontium nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
100 1 3.635 17.176 0.05 0.172 
80 1 2.908 13.741 0.05 0.172 
50 1 1.818 8.588 0.05 0.172 
20 1 0.727 3.435 0.05 0.172 
10 1 0.364 1.718 0.05 0.172 
9 1 0.327 1.546 0.05 0.172 
8 1 0.291 1.374 0.05 0.172 
7 1 0.254 1.202 0.05 0.172 
6 1 0.218 1.031 0.05 0.172 
5 1 0.364 1.718 0.1 0.344 
4 1 0.291 1.374 0.1 0.344 
3 1 0.218 1.031 0.1 0.344 
2 1 0.145 0.687 0.1 0.344 
1 1 0.1 0.473 0.138 0.473 
1 2 0.1 0.473 0.275 0.945 
1 3 0.1 0.473 0.413 1.418 
1 4 0.1 0.473 0.550 1.890 
1 5 0.1 0.473 0.688 2.363 
1 6 0.05 0.236 0.413 1.418 
1 7 0.05 0.236 0.481 1.654 
1 8 0.05 0.236 0.550 1.890 
1 9 0.05 0.236 0.619 2.126 
1 10 0.05 0.236 0.688 2.363 
1 20 0.05 0.236 1.376 4.725 
1 50 0.05 0.236 3.439 11.813 
1 80 0.05 0.236 5.502 18.901 
1 100 0.05 0.236 6.878 23.626 
 
Table 3.4c Strontium nitrate and sodium citrate starting materials along with the molar ratios 
used in each reaction. 
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D 
Ratio Metal Ligand 
Metal Ligand Strontium nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
100 1 5.035 23.794 0.05 0.238 
80 1 4.028 19.035 0.05 0.238 
50 1 2.518 11.897 0.05 0.238 
20 1 1.007 4.759 0.05 0.238 
10 1 0.504 2.379 0.05 0.238 
9 1 0.453 2.141 0.05 0.238 
8 1 0.403 1.903 0.05 0.238 
7 1 0.352 1.666 0.05 0.238 
6 1 0.302 1.428 0.05 0.238 
5 1 0.504 2.379 0.1 0.476 
4 1 0.403 1.903 0.1 0.476 
3 1 0.302 1.428 0.1 0.476 
2 1 0.201 0.952 0.1 0.476 
1 1 0.1007 0.476 0.100 0.476 
1 2 0.1007 0.476 0.200 0.952 
1 3 0.1007 0.476 0.300 1.427 
1 4 0.1007 0.476 0.400 1.903 
1 5 0.1007 0.476 0.500 2.379 
1 6 0.05035 0.238 0.300 1.427 
1 7 0.05035 0.238 0.350 1.665 
1 8 0.05035 0.238 0.400 1.903 
1 9 0.05035 0.238 0.450 2.141 
1 10 0.05035 0.238 0.500 2.379 
1 20 0.05 0.236 0.993 4.725 
1 50 0.05 0.236 2.482 11.813 
1 80 0.05 0.236 3.972 18.901 
1 100 0.05 0.236 4.965 23.626 
 
Table 3.4d Strontium nitrate and citric acid starting materials along with the molar ratios used 
in each reaction. 
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 Iron-Citrate 
 Each reaction was conducted in H2O (10 mL) as well as a H2O/DMF mixture (10 mL).  
Hydrochloric acid (HCl) was added in slow-addition (drop-wise) to the cloudy solutions 
containing sodium citrate until the solutions were clear.  Heat (60 °C) was applied to all solutions 
to increase reactivity and solubility.  Tables 3.5 below shows all the combinations of starting 
materials and ratios used for each reaction.  All iron-citrate solutions ranged in colors from dark 
red to brown and were allowed to undergo slow evaporation (vials were sealed with parafilm and 
a syringe needle was inserted) for crystal growth. 
 
A 
Ratio Metal Ligand 
Metal Ligand Iron chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 1 0.093 0.344 0.1 0.344 
1 10 0.046 0.172 0.5 1.718 
1 100 0.012 0.043 1.25 4.294 
   
B 
Ratio Metal Ligand 
Metal Ligand Iron chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 1 0.192 0.476 0.1 0.476 
1 10 0.096 0.238 0.5 2.379 
1 100 0.024 0.059 1.25 5.948 
 
Table 3.5 Iron chloride/nitrate with sodium citrate/citric acid starting materials varying only 
in ligand ratios. 
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C 
Ratio Metal Ligand 
Metal Ligand Iron nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 1 0.139 0.344 0.1 0.344 
1 10 0.069 0.172 0.5 1.718 
1 100 0.017 0.043 1.25 4.294 
   
D 
Ratio Metal Ligand 
Metal Ligand Iron nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 1 0.192 0.476 0.1 0.476 
1 10 0.096 0.238 0.5 2.379 
1 100 0.024 0.059 1.25 5.948 
 
Table 3.5 Iron chloride/nitrate with sodium citrate/citric acid starting materials varying only 
in ligand ratios. 
 
 
Manganese-Citrate 
 Each reaction was conducted in H2O (10 mL) as well as a H2O/DMF mixture (10 mL).  
Hydrochloric acid (HCl) was added in slow-addition (drop-wise) to the cloudy solutions 
containing sodium citrate until the solutions were clear.  Heat (60 °C) was applied to all solutions 
to increase reactivity and solubility.  Table 3.6 below shows all the combinations of starting 
materials and ratios used for each reaction.  All manganese-citrate solutions ranged in colors 
from light pink to deep purple and were allowed to undergo slow evaporation (vials were sealed 
with parafilm and a syringe needle was inserted) for crystal growth. 
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A 
Ratio Metal Ligand 
Metal Ligand Manganese chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 1 0.1 0.505 0.147 0.505 
1 10 0.05 0.253 0.735 2.526 
1 100 0.005 0.025 0.735 2.526 
	  	  
B 
Ratio Metal Ligand 
Metal Ligand Manganese chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 1 0.1 0.505 0.106 0.505 
1 10 0.05 0.253 0.531 2.526 
1 100 0.005 0.025 0.531 2.526 
	  	  
C 
Ratio Metal Ligand 
Metal Ligand Manganese nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 1 0.1 0.559 0.163 0.559 
1 10 0.05 0.279 0.813 2.794 
1 100 0.005 0.028 0.813 2.794 
	  	  
D 
Ratio Metal Ligand 
Metal Ligand Manganese nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 1 0.1 0.559 0.117 0.559 
1 10 0.05 0.279 0.587 2.794 
1 100 0.005 0.028 0.587 2.794 
 
Table 3.6 Manganese chloride/nitrate with sodium citrate/citric acid starting materials 
varying only in ligand ratios. 
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 Lead-Citrate 
 Each reaction was conducted in H2O (10 mL) as well as a H2O/DMF mixture (10 mL).  
Hydrochloric acid (HCl) was added in slow-addition (drop-wise) to the cloudy solutions 
containing sodium citrate until the solutions were clear.  Heat (60 °C) was applied to all solutions 
to increase reactivity and solubility.  Tables 3.7 below shows all the combinations of starting 
materials and ratios used for each reaction.  All lead-citrate solutions were colorless and allowed 
to undergo slow evaporation (vials were sealed with parafilm and a syringe needle was inserted) 
for crystal growth.  The lead nitrate with sodium citrate in a ratio of 1:20 (highlighted in Table 
3.7) produced a crystal that resulted in a novel crystal structure. 
 
A 
Ratio Metal Ligand 
Metal Ligand Lead chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
100 1 2.388 8.588 0.025 0.086 
50 1 2.388 8.588 0.05 0.172 
20 1 1.911 6.870 0.1 0.344 
10 1 0.478 1.718 0.05 0.172 
5 1 0.478 1.718 0.1 0.344 
1 1 0.096 0.344 0.1 0.344 
1 5 0.096 0.344 0.5 1.718 
1 10 0.048 0.172 0.5 1.718 
1 20 0.048 0.172 1.0 3.435 
1 50 0.048 0.172 2.5 8.588 
1 100 0.010 0.034 1.0 3.435 
 
Table 3.7 Lead chloride/nitrate with sodium citrate/citric acid starting materials with the 
molar ratios used in each reaction. 
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B 
Ratio Metal Ligand 
Metal Ligand Lead chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
100 1 1.323 4.759 0.01 0.048 
50 1 0.662 2.379 0.01 0.048 
20 1 1.323 4.759 0.05 0.238 
10 1 1.323 4.759 0.1 0.476 
5 1 0.662 2.379 0.1 0.476 
1 1 0.132 0.476 0.1 0.476 
1 5 0.132 0.476 0.5 2.379 
1 10 0.132 0.476 1.0 4.759 
1 20 0.066 0.238 1.0 4.759 
1 50 0.066 0.238 2.5 11.897 
1 100 0.013 0.048 1.0 4.759 
 C 
Ratio Metal Ligand 
Metal Ligand Lead nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
100 1 1.138 3.435 0.01 0.034 
50 1 1.138 3.435 0.02 0.069 
20 1 1.138 3.435 0.05 0.172 
10 1 0.569 1.718 0.05 0.172 
5 1 0.569 1.718 0.1 0.344 
1 1 0.114 0.344 0.1 0.344 
1 5 0.114 0.344 0.5 1.718 
1 10 0.114 0.344 1.0 3.435 
1 20 0.057 0.172 1.0 3.435 
1 50 0.057 0.172 2.5 8.588 
1 100 0.011 0.034 1.0 3.435 
 
Table 3.7 Lead chloride/nitrate with sodium citrate/citric acid starting materials with the 
molar ratios used in each reaction. 
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D 
Ratio Metal Ligand 
Metal Ligand Lead nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
100 1 3.940 11.897 0.025 0.119 
50 1 0.788 2.379 0.01 0.048 
20 1 1.576 4.759 0.05 0.238 
10 1 0.788 2.379 0.05 0.238 
5 1 0.788 2.379 0.1 0.476 
1 1 0.158 0.476 0.1 0.476 
1 5 0.158 0.476 0.5 2.379 
1 10 0.158 0.476 1.0 4.759 
1 20 0.079 0.238 1.0 4.759 
1 50 0.079 0.238 2.5 11.897 
1 100 0.032 0.095 2.0 9.517 
 
Table 3.7 Lead chloride/nitrate with sodium citrate/citric acid starting materials with the 
molar ratios used in each reaction. 
 
 
 Tetraphenylphosphonium Bromide (PPh4Br) System 
 Previously prepared metal-citrate solutions were randomly selected and reproduced with 
the addition of PPh4Br as a coligand.  The introduction of a coligand was to induce 
crystallization by potentially occupying coordination sites on the metal.  Each reaction was 
conducted in H2O (10 mL).  Table 3.8 below shows all the combinations of starting materials and 
ratios used for each reaction.  Each metal-citrate solution was allowed to undergo slow 
evaporation (vials were sealed with parafilm and a syringe needle was inserted) for crystal 
growth. 
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Ratio Metal Ligand Co-ligand 
Metal Ligand Barium chloride Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.244 0.999 0.630 2.997 0.084 0.200 
1 1 0.244 0.999 0.210 0.999 0.084 0.200 
3 1 0.244 0.999 0.070 0.333 0.084 0.200 
 Metal Ligand Calcium chloride Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.05 0.340 0.214 1.020 0.029 0.068 
1 1 0.05 0.340 0.071 0.340 0.029 0.068 
3 1 0.05 0.340 0.024 0.113 0.029 0.068 
 Metal Ligand Calcium nitrate Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.08 0.339 0.214 1.016 0.028 0.068 
1 1 0.08 0.339 0.071 0.339 0.028 0.068 
3 1 0.08 0.339 0.024 0.113 0.028 0.068 
 Metal Ligand Cobalt chloride Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.237 0.996 0.628 2.988 0.084 0.199 
1 1 0.237 0.996 0.209 0.996 0.084 0.199 
3 1 0.237 0.996 0.070 0.332 0.084 0.199 
 Metal Ligand Cobalt nitrate Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.292 1.003 0.633 3.010 0.084 0.201 
1 1 0.292 1.003 0.211 1.003 0.084 0.201 
3 1 0.292 1.003 0.070 0.334 0.084 0.201 
 Metal Ligand Copper chloride Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.086 0.504 0.318 1.513 0.042 0.101 
1 1 0.086 0.504 0.106 0.504 0.042 0.101 
3 1 0.086 0.504 0.035 0.168 0.042 0.101 
 
Table 3.8 Various metals and ligands reacted with the coligand PPh4Br. 
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Ratio Metal Ligand Co-ligand 
Metal Ligand Iron chloride Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.27 0.999 0.630 2.997 0.084 0.200 
1 1 0.27 0.999 0.210 0.999 0.084 0.200 
3 1 0.27 0.999 0.070 0.333 0.084 0.200 
 Metal Ligand Iron nitrate Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.235 0.582 0.367 1.745 0.049 0.116 
1 1 0.235 0.582 0.122 0.582 0.049 0.116 
3 1 0.235 0.582 0.041 0.194 0.049 0.116 
 Metal Ligand Magnesium nitrate Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.252 0.983 0.620 2.948 0.082 0.197 
1 1 0.252 0.983 0.207 0.983 0.082 0.197 
3 1 0.252 0.983 0.069 0.328 0.082 0.197 
 Metal Ligand Manganese chloride Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.194 0.980 0.618 2.941 0.082 0.196 
1 1 0.194 0.980 0.206 0.980 0.082 0.196 
3 1 0.194 0.980 0.069 0.327 0.082 0.196 
  
Metal Ligand Nickel chloride Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.237 0.997 0.629 2.991 0.084 0.199 
1 1 0.237 0.997 0.210 0.997 0.084 0.199 
3 1 0.237 0.997 0.070 0.332 0.084 0.199 
  
Metal Ligand Nickel nitrate Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.293 1.008 0.635 3.023 0.084 0.202 
1 1 0.293 1.008 0.212 1.008 0.084 0.202 
3 1 0.293 1.008 0.071 0.336 0.084 0.202 
 
Table 3.8 Various metals and ligands reacted with the coligand PPh4Br. 
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Ratio Metal Ligand Co-ligand 
Metal Ligand Strontium chloride Citric acid PPh4Br 
    (grams) (mmol) (grams) (mmol) (grams) (mmol) 
1 3 0.265 0.995 0.628 2.986 0.083 0.199 
1 1 0.265 0.995 0.209 0.995 0.083 0.199 
3 1 0.265 0.995 0.070 0.332 0.083 0.199 
 
Table 3.8 Various metals and ligands reacted with the coligand PPh4Br. 
 
 
 Piperazine-N,N’bis(2-ethanesulfonic acid) (PIPES) Buffer System 
 Barium, calcium, cobalt, copper, iron, magnesium, manganese, nickel, and strontium 
metals were reacted with various citrate salts in a 50 mM PIPES buffer solution at a pH of 7.0 
(10 mL).  This was to mimic biological conditions as well as the radio flux assays as precisely as 
possible.  Tables 3.9a-3.9c below shows all the combinations of starting materials and ratios used 
for each reaction.  Each metal-citrate solution had its own unique color: barium – colorless; 
calcium – colorless; cobalt – purple; copper – blue/green; iron – red/brown; magnesium – 
colorless; manganese – pink; nickel – green; strontium – colorless; and were allowed to undergo 
slow evaporation (vials were sealed with parafilm and a syringe needle was inserted) for crystal 
growth.   
 
Ratio Metal Ligand 
Metal Ligand Barium chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.244 0.999 0.872 2.997 
1 1 0.244 0.999 0.291 0.999 
3 1 0.244 0.999 0.097 0.333 
 
Table 3.9a Various metal chlorides/nitrates with sodium citrate reacted in a 50 mM PIPES 
buffer system. 
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Ratio Metal Ligand 
Metal Ligand Calcium chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.05 0.340 0.297 1.020 
1 1 0.05 0.340 0.099 0.340 
3 1 0.05 0.340 0.033 0.113 
 Metal Ligand Calcium nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.08 0.339 0.296 1.016 
1 1 0.08 0.339 0.099 0.339 
3 1 0.08 0.339 0.033 0.113 
 Metal Ligand Cobalt chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.239 1.004 0.877 3.013 
1 1 0.239 1.004 0.292 1.004 
3 1 0.239 1.004 0.097 0.335 
 Metal Ligand Cobalt nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.294 1.010 0.882 3.031 
1 1 0.294 1.010 0.294 1.010 
3 1 0.294 1.010 0.098 0.337 
  
Metal Ligand Copper chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.084 0.493 0.430 1.478 
1 1 0.084 0.493 0.143 0.493 
3 1 0.084 0.493 0.048 0.164 
 Metal Ligand Copper nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.294 1.264 1.104 3.792 
1 1 0.294 1.264 0.368 1.264 
3 1 0.294 1.264 0.123 0.421 
 
Table 3.9a Various metal chlorides/nitrates with sodium citrate reacted in a 50 mM PIPES 
buffer system. 
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Ratio Metal Ligand 
Metal Ligand Iron chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.272 1.006 0.879 3.019 
1 1 0.272 1.006 0.293 1.006 
3 1 0.272 1.006 0.098 0.335 
 Metal Ligand Iron nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.294 0.728 0.636 2.183 
1 1 0.294 0.728 0.212 0.728 
3 1 0.294 0.728 0.071 0.243 
 Metal Ligand Magnesium nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.255 0.995 0.868 2.984 
1 1 0.255 0.995 0.289 0.995 
3 1 0.255 0.995 0.096 0.332 
 Metal Ligand Manganese chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.196 0.990 0.865 2.971 
1 1 0.196 0.990 0.288 0.990 
3 1 0.196 0.990 0.096 0.330 
 Ratio Metal Ligand 
Metal Ligand Nickel chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.236 0.993 0.867 2.979 
1 1 0.236 0.993 0.289 0.993 
3 1 0.236 0.993 0.096 0.331 
 Metal Ligand Nickel nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.287 0.987 0.862 2.961 
1 1 0.287 0.987 0.287 0.987 
3 1 0.287 0.987 0.096 0.329 
 
Table 3.9a Various metal chlorides/nitrates with sodium citrate reacted in a 50 mM PIPES 
buffer system. 
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Ratio Metal Ligand 
Metal Ligand Strontium chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.268 1.007 0.879 3.020 
1 1 0.268 1.007 0.293 1.007 
3 1 0.268 1.007 0.098 0.336 
 
Table 3.9a Various metal chlorides/nitrates with sodium citrate reacted in a 50 mM PIPES 
buffer system. 
 
Ratio Metal Ligand 
Metal Ligand Barium chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.244 0.999 0.630 2.997 
1 1 0.244 0.999 0.210 0.999 
3 1 0.244 0.999 0.070 0.333 
 Metal Ligand Calcium chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.05 0.340 0.214 1.020 
1 1 0.05 0.340 0.071 0.340 
3 1 0.05 0.340 0.024 0.113 
  
Metal Ligand Calcium nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.08 0.339 0.214 1.016 
1 1 0.08 0.339 0.071 0.339 
3 1 0.08 0.339 0.024 0.113 
 Metal Ligand Cobalt chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.237 0.996 0.628 2.988 
1 1 0.237 0.996 0.209 0.996 
3 1 0.237 0.996 0.070 0.332 
 
Table 3.9b Various metal chlorides/nitrates with citric acid reacted in a 50 mM PIPES buffer 
system. 
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Ratio Metal Ligand 
Metal Ligand Cobalt nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.292 1.003 0.633 3.010 
1 1 0.292 1.003 0.211 1.003 
3 1 0.292 1.003 0.070 0.334 
  
Metal Ligand Copper chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.086 0.504 0.318 1.513 
1 1 0.086 0.504 0.106 0.504 
3 1 0.086 0.504 0.035 0.168 
  
Metal Ligand Copper nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.235 1.010 0.637 3.031 
1 1 0.235 1.010 0.212 1.010 
3 1 0.235 1.010 0.071 0.337 
 Metal Ligand Iron chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.27 0.999 0.630 2.997 
1 1 0.27 0.999 0.210 0.999 
3 1 0.27 0.999 0.070 0.333 
  
Metal Ligand Iron nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.235 0.582 0.367 1.745 
1 1 0.235 0.582 0.122 0.582 
3 1 0.235 0.582 0.041 0.194 
 Metal Ligand Magnesium nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.252 0.983 0.620 2.948 
1 1 0.252 0.983 0.207 0.983 
3 1 0.252 0.983 0.069 0.328 
 
Table 3.9b Various metal chlorides/nitrates with citric acid reacted in a 50 mM PIPES buffer 
system. 
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Ratio Metal Ligand 
Metal Ligand Manganese chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.194 0.980 0.618 2.941 
1 1 0.194 0.980 0.206 0.980 
3 1 0.194 0.980 0.069 0.327 
 Metal Ligand Nickel chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.237 0.997 0.629 2.991 
1 1 0.237 0.997 0.210 0.997 
3 1 0.237 0.997 0.070 0.332 
 Metal Ligand Nickel nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.293 1.008 0.635 3.023 
1 1 0.293 1.008 0.212 1.008 
3 1 0.293 1.008 0.071 0.336 
  
Metal Ligand Strontium chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.265 0.995 0.628 2.986 
1 1 0.265 0.995 0.209 0.995 
3 1 0.265 0.995 0.070 0.332 
 
Table 3.9b Various metal chlorides/nitrates with citric acid reacted in a 50 mM PIPES buffer 
system. 
 
Ratio Metal Ligand 
Metal Ligand Barium chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.244 0.999 0.729 2.997 
1 1 0.244 0.999 0.243 0.999 
3 1 0.244 0.999 0.081 0.333 
 
Table 3.9c Various metal chlorides/nitrates with ammonium citrate reacted in a 50 mM 
PIPES buffer system. 
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Ratio Metal Ligand 
Metal Ligand Calcium chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.05 0.340 0.248 1.020 
1 1 0.05 0.340 0.083 0.340 
3 1 0.05 0.340 0.028 0.113 
 Metal Ligand Calcium nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.08 0.339 0.247 1.016 
1 1 0.08 0.339 0.082 0.339 
3 1 0.08 0.339 0.027 0.113 
 Metal Ligand Cobalt chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.236 0.992 0.724 2.976 
1 1 0.236 0.992 0.241 0.992 
3 1 0.236 0.992 0.080 0.331 
 Metal Ligand Cobalt nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.292 1.003 0.732 3.010 
1 1 0.292 1.003 0.244 1.003 
3 1 0.292 1.003 0.081 0.334 
  
Metal Ligand Copper chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.084 0.493 0.360 1.478 
1 1 0.084 0.493 0.120 0.493 
3 1 0.084 0.493 0.040 0.164 
  
Metal Ligand Copper nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.235 1.010 0.737 3.031 
1 1 0.235 1.010 0.246 1.010 
3 1 0.235 1.010 0.082 0.337 
 
Table 3.9c Various metal chlorides/nitrates with ammonium citrate reacted in a 50 mM 
PIPES buffer system. 
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Ratio Metal Ligand 
Metal Ligand Iron chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.271 1.003 0.732 3.008 
1 1 0.271 1.003 0.244 1.003 
3 1 0.271 1.003 0.081 0.334 
 Metal Ligand Iron nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.235 0.582 0.424 1.745 
1 1 0.235 0.582 0.141 0.582 
3 1 0.235 0.582 0.047 0.194 
 Metal Ligand Magnesium nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.256 0.998 0.728 2.995 
1 1 0.256 0.998 0.243 0.998 
3 1 0.256 0.998 0.081 0.333 
 Metal Ligand Manganese chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.197 0.995 0.726 2.986 
1 1 0.197 0.995 0.242 0.995 
3 1 0.197 0.995 0.081 0.332 
 Metal Ligand Nickel chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.236 0.993 0.724 2.979 
1 1 0.236 0.993 0.241 0.993 
3 1 0.236 0.993 0.080 0.331 
  
Metal Ligand Nickel nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.29 0.997 0.728 2.992 
1 1 0.29 0.997 0.243 0.997 
3 1 0.29 0.997 0.081 0.332 
 
Table 3.9c Various metal chlorides/nitrates with ammonium citrate reacted in a 50 mM 
PIPES buffer system. 
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Ratio Metal Ligand 
Metal Ligand Strontium chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.267 1.003 0.732 3.009 
1 1 0.267 1.003 0.244 1.003 
3 1 0.267 1.003 0.081 0.334 
 
Table 3.9c Various metal chlorides/nitrates with ammonium citrate reacted in a 50 mM 
PIPES buffer system. 
 
 
Counter-Cations (NaOH, KOH, NH4OH) and Solvents (H2O, DMF, H2O/DMF) 
 
 Previously prepared metal-citrate solutions were randomly selected and reproduced with 
the addition of various bases.  Many of the published metal-citrate complexes used bases to 
balance the potentially highly negatively charged citrate ion and act as charge compensators for 
the metal-citrate complex.  The most commonly used bases were NaOH (Table 3.10a), KOH 
(Table 3.10b), and NH4OH (Table 3.10c).  Each base was added drop-wise until the desired pH 
was obtained.  Additionally, different solvent systems, H2O (10 mL) (Table 3.11a), DMF (10 
mL) (Table 3.11b), H2O/DMF (10 mL) (Table 3.11c), were reinvestigated.  Each metal-citrate 
solution was allowed to undergo slow evaporation (vials were sealed with parafilm and a syringe 
needle was inserted) for crystal growth. 
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Ratio Metal Ligand pH 
Metal Ligand Calcium nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.237 1.004 0.633 3.011 5 
1 1 0.237 1.004 0.211 1.004 5 
3 1 0.237 1.004 0.070 0.335 5 
 	  
Metal Ligand Iron chloride Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.270 0.999 0.630 2.997 5 
1 1 0.270 0.999 0.210 0.999 5 
3 1 0.270 0.999 0.070 0.333 5 
 	  
Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 5 
1 1 0.212 1.002 0.211 1.002 5 
3 1 0.212 1.002 0.070 0.334 5 
	   Metal Ligand Calcium nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.237 1.004 0.633 3.011 6 
1 1 0.237 1.004 0.211 1.004 6 
3 1 0.237 1.004 0.070 0.335 6 
 	  
Metal Ligand Iron chloride Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.270 0.999 0.630 2.997 6 
1 1 0.270 0.999 0.210 0.999 6 
3 1 0.270 0.999 0.070 0.333 6 
	   Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 6 
1 1 0.212 1.002 0.211 1.002 6 
3 1 0.212 1.002 0.070 0.334 6 
 
Table 3.10a Various metal chlorides/nitrates with citric acid in H2O with pH adjusted by 
NaOH. 
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Ratio Metal Ligand pH 
Metal Ligand Calcium nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.237 1.004 0.633 3.011 7 
1 1 0.237 1.004 0.211 1.004 7 
3 1 0.237 1.004 0.070 0.335 7 
	   Metal Ligand Iron chloride Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.270 0.999 0.630 2.997 7 
1 1 0.270 0.999 0.210 0.999 7 
3 1 0.270 0.999 0.070 0.333 7 
 Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 7 
1 1 0.212 1.002 0.211 1.002 7 
3 1 0.212 1.002 0.070 0.334 7 
	   Metal Ligand Calcium nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.237 1.004 0.633 3.011  8-9 
1 1 0.237 1.004 0.211 1.004  8-9 
3 1 0.237 1.004 0.070 0.335  8-9 
 	  
Metal Ligand Iron chloride Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.270 0.999 0.630 2.997 8-9 
1 1 0.270 0.999 0.210 0.999 8-9 
3 1 0.270 0.999 0.070 0.333 8-9 
	   	  
Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 8-9 
1 1 0.212 1.002 0.211 1.002 8-9 
3 1 0.212 1.002 0.070 0.334 8-9 
 
Table 3.10a Various metal chlorides/nitrates with citric acid in H2O with pH adjusted by 
NaOH. 
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Ratio Metal Ligand pH 
Metal Ligand Calcium nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.237 1.004 0.633 3.011 6 
1 1 0.237 1.004 0.211 1.004 6 
3 1 0.237 1.004 0.070 0.335 6 
	  	  
Metal Ligand Iron chloride Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.270 0.999 0.630 2.997 6 
1 1 0.270 0.999 0.210 0.999 6 
3 1 0.270 0.999 0.070 0.333 6 
	   Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 6 
1 1 0.212 1.002 0.211 1.002 6 
3 1 0.212 1.002 0.070 0.334 6 
	   Metal Ligand Calcium nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.237 1.004 0.633 3.011 7 
1 1 0.237 1.004 0.211 1.004 7 
3 1 0.237 1.004 0.070 0.335 7 
	   Metal Ligand Iron chloride Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.270 0.999 0.630 2.997 7 
1 1 0.270 0.999 0.210 0.999 7 
3 1 0.270 0.999 0.070 0.333 7 
	   Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 7 
1 1 0.212 1.002 0.211 1.002 7 
3 1 0.212 1.002 0.070 0.334 7 
 
Table 3.10b Various metal chlorides/nitrates with citric acid in H2O with pH adjusted by 
KOH. 
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Ratio Metal Ligand pH 
Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 8 
1 1 0.212 1.002 0.211 1.002 8 
3 1 0.212 1.002 0.070 0.334 8 
 
Table 3.10b Various metal chlorides/nitrates with citric acid in H2O with pH adjusted by 
KOH. 
 
 
Ratio Metal Ligand pH 
Metal Ligand Calcium nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.237 1.004 0.633 3.011 6 
1 1 0.237 1.004 0.211 1.004 6 
3 1 0.237 1.004 0.070 0.335 6 
	   Metal Ligand Iron chloride Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.270 0.999 0.630 2.997 6 
1 1 0.270 0.999 0.210 0.999 6 
3 1 0.270 0.999 0.070 0.333 6 
	   Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 6 
1 1 0.212 1.002 0.211 1.002 6 
3 1 0.212 1.002 0.070 0.334 6 
	   Metal Ligand Calcium nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.237 1.004 0.633 3.011 7 
1 1 0.237 1.004 0.211 1.004 7 
3 1 0.237 1.004 0.070 0.335 7 
 
Table 3.10c Various metals and ligands in H2O with pH adjusted by NH4OH. 
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Ratio Metal Ligand pH 
Metal Ligand Iron chloride Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.270 0.999 0.630 2.997 7 
1 1 0.270 0.999 0.210 0.999 7 
3 1 0.270 0.999 0.070 0.333 7 
	   Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 7 
1 1 0.212 1.002 0.211 1.002 7 
3 1 0.212 1.002 0.070 0.334 7 
 Metal Ligand Strontium Nitrate Citric acid   
    (grams) (mmol) (grams) (mmol)   
1 3 0.212 1.002 0.632 3.005 8 
1 1 0.212 1.002 0.211 1.002 8 
3 1 0.212 1.002 0.070 0.334 8 
 
Table 3.10c Various metals and ligands in H2O with pH adjusted by NH4OH. 
 
Ratio Metal Ligand 
Metal Ligand Calcium chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.05 0.340 0.214 1.020 
1 1 0.05 0.340 0.071 0.340 
3 1 0.05 0.340 0.024 0.113 
	   Metal Ligand Calcium chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.05 0.340 0.248 1.020 
1 1 0.05 0.340 0.083 0.340 
3 1 0.05 0.340 0.028 0.113 
 
Table 3.11a Various metal chlorides/nitrates with sodium citrate/citric acid/ammonium citrate 
in H2O. 
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Ratio Metal Ligand 
Metal Ligand Cobalt chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.239 1.004 0.877 3.013 
1 1 0.239 1.004 0.292 1.004 
3 1 0.239 1.004 0.097 0.335 
      
Metal Ligand Iron nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.235 0.582 0.367 1.745 
1 1 0.235 0.582 0.122 0.582 
3 1 0.235 0.582 0.041 0.194 
	   Metal Ligand Iron nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.235 0.582 0.424 1.745 
1 1 0.235 0.582 0.141 0.582 
3 1 0.235 0.582 0.047 0.194 
	   Metal Ligand Nickel chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.236 0.993 0.867 2.979 
1 1 0.236 0.993 0.289 0.993 
3 1 0.236 0.993 0.096 0.331 
	   Metal Ligand Nickel chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.237 0.997 0.629 2.991 
1 1 0.237 0.997 0.210 0.997 
3 1 0.237 0.997 0.070 0.332 
	   Metal Ligand Nickel chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.236 0.993 0.724 2.979 
1 1 0.236 0.993 0.241 0.993 
3 1 0.236 0.993 0.080 0.331 
 
Table 3.11a Various metal chlorides/nitrates with sodium citrate/citric acid/ammonium citrate 
in H2O. 
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Ratio Metal Ligand 
Metal Ligand Strontium chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.265 0.995 0.628 2.986 
1 1 0.265 0.995 0.209 0.995 
3 1 0.265 0.995 0.070 0.332 
 Ratio Metal Ligand 
Metal Ligand Strontium chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.267 1.003 0.732 3.009 
1 1 0.267 1.003 0.244 1.003 
3 1 0.267 1.003 0.081 0.334 
 
Table 3.11a Various metal chlorides/nitrates with sodium citrate/citric acid/ammonium citrate 
in H2O. 
 
 
Ratio Metal Ligand 
Metal Ligand Calcium nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.08 0.339 0.214 1.016 
1 1 0.08 0.339 0.071 0.339 
3 1 0.08 0.339 0.024 0.113 
 Metal Ligand Calcium nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.08 0.339 0.247 1.016 
1 1 0.08 0.339 0.082 0.339 
3 1 0.08 0.339 0.027 0.113 
 Ratio Metal Ligand 
Metal Ligand Iron nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.235 0.582 0.367 1.745 
1 1 0.235 0.582 0.122 0.582 
3 1 0.235 0.582 0.041 0.194 
 
Table 3.11b Various metal chlorides/nitrates/sulfates with citric acid/ammonium citrate in 
DMF. 
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Ratio Metal Ligand 
Metal Ligand Iron nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.235 0.582 0.424 1.745 
1 1 0.235 0.582 0.141 0.582 
3 1 0.235 0.582 0.047 0.194 
 Metal Ligand Strontium chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.265 0.995 0.628 2.986 
1 1 0.265 0.995 0.209 0.995 
3 1 0.265 0.995 0.070 0.332 
 Metal Ligand Strontium chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.267 1.003 0.732 3.009 
1 1 0.267 1.003 0.244 1.003 
3 1 0.267 1.003 0.081 0.334 
 Metal Ligand Strontium sulfate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.184 1.002 0.632 3.005 
1 1 0.184 1.002 0.211 1.002 
3 1 0.184 1.002 0.070 0.334 
 Metal Ligand Strontium sulfate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.184 1.002 0.731 3.005 
1 1 0.184 1.002 0.244 1.002 
3 1 0.184 1.002 0.081 0.334 
 
Table 3.11b Various metal chlorides/nitrates/sulfates with citric acid/ammonium citrate in 
DMF. 
 
 
 
 
	   92 
Ratio Metal Ligand 
Metal Ligand Calcium nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.080 0.339 0.214 1.016 
1 1 0.080 0.339 0.071 0.339 
3 1 0.080 0.339 0.024 0.113 
 Metal Ligand Strontium nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.212 1.002 0.632 3.005 
1 1 0.212 1.002 0.211 1.002 
3 1 0.212 1.002 0.070 0.334 
 
Table 3.11c Various metal nitrates with citric acid in H2O/DMF mixture. 
 
 
 Recrystallization Using Methanol 
 Many of the solutions that were prepared produced powders and crystals of insufficient 
quality for X-ray crystallography.  Some of these solutions were chosen at random to attempt 
recrystallization to produce better quality crystals.  Each solution was dissolved with a minimal 
amount of hot methanol and allowed to cool to room temperature to undergo slow evaporation 
for crystal growth.  Table 3.12 below shows all solutions chosen for recrystallization. 
 
Ratio Metal Ligand 
Metal Ligand Calcium sulfate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.179 1.040 0.655 3.119 
1 1 0.179 1.040 0.218 1.040 
3 1 0.179 1.040 0.073 0.347 
 
Table 3.12 Solutions chosen for recrystallization using hot methanol. 
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Ratio Metal Ligand 
Metal Ligand Calcium sulfate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.179 1.040 0.759 3.119 
1 1 0.179 1.040 0.253 1.040 
3 1 0.179 1.040 0.084 0.347 
 Metal Ligand Cobalt chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.239 1.004 0.877 3.013 
1 1 0.239 1.004 0.292 1.004 
3 1 0.239 1.004 0.097 0.335 
 Metal Ligand Iron chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.27 0.999 0.630 2.997 
1 1 0.27 0.999 0.210 0.999 
3 1 0.27 0.999 0.070 0.333 
 Metal Ligand Iron chloride Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.271 1.003 0.732 3.008 
1 1 0.271 1.003 0.244 1.003 
3 1 0.271 1.003 0.081 0.334 
 Metal Ligand Strontium nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
1 3 0.212 1.002 0.632 3.005 
1 1 0.212 1.002 0.211 1.002 
3 1 0.212 1.002 0.070 0.334 
 Metal Ligand Strontium nitrate Ammonium citrate 
    (grams) (mmol) (grams) (mmol) 
1 3 0.212 1.002 0.731 3.005 
1 1 0.212 1.002 0.244 1.002 
3 1 0.212 1.002 0.081 0.334 
 
Table 3.12 Solutions chosen for recrystallization using hot methanol. 
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 Hydrothermal Syntheses 
 Each reaction was carried out in a 3:2 (metal:ligand) ratio in H2O (8 mL).  Hydrochloric 
acid (HCl) was added drop-wise until the desired pH was obtained.  The temperature and 
duration of the reactions were also varied.  Table 3.13a below shows the different combinations 
of starting materials used.  Table 3.13b below shows all the combinations of starting materials, 
acids/bases, temperatures, and time.  Additionally, Table 3.14 below shows all the reactions that 
produced powders.  Unfortunately, none produced any crystals. 
 
A 
Ratio Metal Ligand 
Metal Ligand Strontium chloride Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
3 2 0.374 1.405 0.273 0.937 
            
B 
Ratio Metal Ligand 
Metal Ligand Strontium chloride Citric acid 
    (grams) (mmol) (grams) (mmol) 
3 2 0.373 1.401 0.196 0.934 
            
C 
Ratio Metal Ligand 
Metal Ligand Strontium nitrate Sodium citrate 
    (grams) (mmol) (grams) (mmol) 
3 2 0.374 1.767 0.343 1.178 
  
D 
Ratio Metal Ligand 
Metal Ligand Strontium nitrate Citric acid 
    (grams) (mmol) (grams) (mmol) 
3 2 0.373 1.763 0.247 1.175 
 
Table 3.13a Strontium chloride and citric acid starting materials. 
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Reaction Base Acid Temperature (°C) Days 
A       170 4 
B       170 4 
C       170 4 
D       170 4 
A     HCl (pH 1) 170 4 
A     HCl (pH 2) 170 4 
A     HCl (pH 3) 170 4 
A     HCl (pH 4) 170 4 
A 
TMAH       
(grams) (mmol)       
0.128 1.405   170 4 
A 
TBAH       
(grams) (mmol)       
0.365 1.405   170 4 
A 
TEAH       
(grams) (mmol)       
0.207 1.405   200 4 
C 
TMAH       
(grams) (mmol)       
0.161 1.767   170 4 
C 
TBAH       
(grams) (mmol)       
0.459 1.767   170 4 
C 
TEAH       
(grams) (mmol)       
0.055 0.374   200 4 
 
Table 3.13b List of starting materials, acid/base used, and reaction conditions (temperature and 
time).  TBAH – tetrabutylammonium hydroxide; TMAH – tetramethylammonium hydroxide; 
TEAH – tetraethylammonium hydroxide; TEA – triethylamine; 1,10-C12H8N2 – 1,10’-
phenanthroline. 
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Reaction Base Acid Temperature (°C) Days 
C 
TEAH       
(grams) (mmol)       
0.055 0.374   200 4 
A 
TEA       
(grams) (mmol)       
0.142 1.405   170 4 
B 
TEA       
(grams) (mmol)       
0.142 1.401   200 4 
C 
TEA       
(grams) (mmol)       
0.179 1.767   200 4 
D 
TEA       
(grams) (mmol)       
0.178 1.763   200 4 
A 
2,2'-Bipyridyl       
(grams) (mmol)       
0.219 1.405   170 4 
B 
2,2'-Bipyridyl       
(grams) (mmol)       
0.219 1.401   200 4 
C 
2,2'-Bipyridyl       
(grams) (mmol)       
0.276 1.767   200 4 
D 
2,2'-Bipyridyl       
(grams) (mmol)       
0.275 1.763   200 4 
 
Table 3.13b List of starting materials, acid/base used, and reaction conditions (temperature and 
time).  TBAH – tetrabutylammonium hydroxide; TMAH – tetramethylammonium hydroxide; 
TEAH – tetraethylammonium hydroxide; TEA – triethylamine; 1,10-C12H8N2 – 1,10’-
phenanthroline. 
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Reaction Base Acid Temperature (°C) Days 
A 
1,10-C12H8N2       
(grams) (mmol)       
0.253 1.405   170 4 
B 
1,10-C12H8N2       
(grams) (mmol)       
0.253 1.401   200 4 
C 
1,10-C12H8N2       
(grams) (mmol)       
0.318 1.767   200 4 
D 
1,10-C12H8N2       
(grams) (mmol)       
0.318 1.763   200 4 
A       200 4 
B       200 4 
C       200 4 
D       200 4 
 
Table 3.13b List of starting materials, acid/base used, and reaction conditions (temperature and 
time).  TBAH – tetrabutylammonium hydroxide; TMAH – tetramethylammonium hydroxide; 
TEAH – tetraethylammonium hydroxide; TEA – triethylamine; 1,10-C12H8N2 – 1,10’-
phenanthroline. 
 
Metal Ligand Base Acid Temp (°C) Days 
Strontium chloride Sodium citrate   170 4 
Strontium chloride Citric acid   170 4 
Strontium nitrate Sodium citrate   170 4 
Strontium nitrate Citric acid   170 4 
Strontium chloride Sodium citrate  HCl (pH 3) 170 4 
Strontium chloride Sodium citrate  HCl (pH 4) 170 4 
Strontium chloride Sodium citrate  HCl (pH 5) 170 4 
Strontium chloride Sodium citrate TMAH  170 4 
Strontium chloride Sodium citrate TBAH  170 4 
Strontium nitrate Sodium citrate TMAH  170 4 
Strontium nitrate Sodium citrate TBAH  170 4 
Strontium chloride Sodium citrate   200 4 
Strontium nitrate Sodium citrate   200 4 
 
Table 3.14 Hydrothermal reactions from Table 3.14 that produced powders. 
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PART II. SYNTHESIS AND CHARACTERIZATOIN OF NOVEL BIFUNCTIONAL 
SINGLE AMINO ACID CHELATES (SAAC) FOR NUCLEAR IMAGING. 
 
Chapter 4. Introduction 
 
4.1 Nuclear Medicine 
 The main goal of medical diagnostics using molecular imaging probes is to provide rapid, 
non-invasive assessment of physiology, pathology, and/or organ function.  A key benefit of using 
molecular imaging is that it enables the early detection of disease, which allows for rapid 
deployment of therapies.  Therapies employed at the early onset of disease are often less invasive 
than procedures needed for more advanced cases.  Early detection also allows for a wider range 
of choices in selecting the best and advantageous methods for treatment.  This method of 
molecular imaging can lead to improved outcomes, quality of care, and patient safety by 
targeting more specific areas with fewer complications and shorter hospital stays.  One particular 
kind of molecular imaging called radioactive probes offer a number of advantages over other 
existing and less sensitive methods for imaging specific biological targets, especially those 
present in low concentrations.1-11 
 The two main modalities in nuclear medicine are single photon emission computed 
tomography (SPECT) and positron emission tomography (PET).  PET offers higher resolution 
and sensitivity, while SPECT offers radioisotopes that are easily accessible, longer-lived, and 
cheaper.  SPECT radiotracers are generally small molecules (MW < 2000) labeled with gamma-
emitting isotopes for diagnosis, such as 123I, 111In, 67Ga, and 99mTc.  99mTc (m = metastable) has 
become the most widely used radioisotope for diagnosis and also the go-to for nuclear medicine 
due to its relatively straightforward chemistry.9,12-35 
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 4.1.1 Technetium-99m 
 99mTc for radiopharmaceutical applications has been favored mainly due to its ideal 
nuclear properties as well as its convenient availability from commercial generators.  The 140-
keV γ–ray emission (89% abundance) is close to optimal for imaging via commercially available 
gamma cameras.  The absence of corpuscular radiation allows for the injection of activities of 
more than 30 mCi with low radiation exposure to the patient.21  The 6-hour half-life is 
adequately long enough to allow pharmaceutical preparation and in vivo accumulation in the 
target tissue, but short enough to minimize radiation dose to the patient. 
 Technetium is obtained from a generator, which is easily shielded, as pertechnetate (Na 
99mTcO4) in high specific activity.  This property is key to developing high sensitivity molecular 
imaging methods. 
 However, technetium does not come without its limitations, one of them being that it is a 
transition metal, which complicates its labeling chemistry.  99mTc cannot be directly substituted 
for a hydrogen atom in a targeting vector, contrary to radiohalogens, as the products are 
generally unstable.  As a result, the development of technetium-based imaging agents requires 
understanding of the coordination chemistry of technetium and the design of suitable ligands for 
development of suitably robust and effective molecular imaging probes. 
 One of the complications in the development of radiopharmaceuticals is the inability to 
determine the performance and outcome of the compounds at the cellular and subcellular level.  
This causes problems when trying to ascertain the mechanisms responsible for the specificity and 
localization of the compound.  Substitution of the radiolabel with a fluorescent dye may solve 
this problem but might alter the physicochemical properties to render the results useless.  An 
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ideal system would be one in which the fluorescent and radioactive compounds are 
isostructural.36,37 
 
4.1.2 Rhenium  
Rhenium has been used to prepare probes, since its compounds are often isostructural to 
analogous technetium species.  Complimentary pairs of fluorescent and radioactive probes could 
be prepared using the {99mTc(CO)3}+ and {Re(CO)3}+ cores.  {Re(CO)3}+ complexes are 
fluorescent in the presence of appropriate aromatic donor ligands.38-40  Luminescent Re(I) probes 
are helpful in studying biological processes due to their long-lifetime, polarized emission, and 
large Stoke’s shift.38-41  If the coordination chemistry of rhenium and technetium are similar, 
designing a ligand that forms a fluorescent rhenium complex and stable 99mTc complex should be 
possible.  This would also allow for the ability for the two to be correlated to a targeting agent 
and would result in the images obtained on a fluorescent microscope to be compared with 
radioimaging studies due to the fact that the two structures would be nearly identical.42 
  
4.2 Bifunctional Chelates 
One approach for designing receptor/site-specific 99mTc compounds is the conjugate (or 
pendant) method.  This involves tethering a 99mTc-chelate moiety to a molecule that possesses a 
high binding affinity to a receptor.  Bifunctional chelates are an effective strategy for linking the 
radioactive metal cations to biologically active molecules.34,43-48  Figure 4.1 below represents the 
three-component system of a biologically active molecule, a bifunctional chelate/spacer group, 
and the radioactive metal.  This requires the receptor ligand to have a high affinity on the 
targeting molecule, a bifunctional chelator for the conjugation of the receptor, and coordination 
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of the radionuclide.  The bifunctional chelate allows for the formation of a secure linkage bond 
to the metal radionuclide to prevent leakage in vivo at one terminus and to provide a second 
functional group for linking to a targeting vector.    
 
 
Figure 4.1 Schematic representation of the bifunctional chelate strategy. 
 
4.3 Core Structures for Technetium and Rhenium 
Technetium and rhenium display the unusual trait that characterized compounds for all 
formal oxidation states between -1 and +7 occur.49  This suggests considerable structural 
diversity for the development of radiopharmaceuticals as well as the accessibility of a variety of 
oxidation states leading to complex product mixtures and the potential for labile complexes.  
However, the stable and readily accessible oxidation states are characterized by chemically 
robust core structures.  Figure 4.2 below shows some of the more common core structures. 
Although the [Tc(V)O]3+ moiety has been extensively studied, it has become a less 
popular field of study due to the discovery of a convenient means to make Tc(I) complexes, 
which will be described in further detail in the next chapter.50-83 
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Figure 4.2 Common core structures for technetium and rhenium: (a) Tc(V)-oxo; (b) Tc(V)-
nitrido; (c) Tc(V)-imido; (d) Tc(I)-tricarbonyl; (e) Tc(III)-hydrazino. 
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Chapter 5. Synthesis, Characterization, and Fluorescence Studies on Single Amino Acid 
Chelates (SAAC). 
 
 
 
5.1 Introduction 
 One particular strategy of creating radiolabeled biomolecules focuses on the design of 
single amino acid chelates (SAAC), novel bifunctional chelators that can be constructed from 
various amino acids and their analogues.  The chelating terminus of the SAAC forms an inert 
complex and is designed for effective coordination to a radionuclide while the other terminus can 
be incorporated into a variety of biomolecules.  Figure 5.1 below represents the concept of the 
SAAC.1 
 
 
Figure 5.1 Schematic representation of the single amino acid chelate (SAAC) design that 
modifies a natural or synthetic amino acid to incorporate: (red) tridentate chelate terminus; 
(blue/teal) another terminus on the other end for attachment to small peptides; (green) 
tether/linker that can be designed for optimization. 
 
 While metal-oxo and metal-organo-hydrazino cores remain popular, other core 
geometries such as {M(CO)3}+ have generated a renewed interest in the design of 99mTc 
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radiopharmaceuticals.2-12  The coordination chemistry of the metal is of high significance and 
must be taken into consideration for the development of an effective radioconjugate imager.  The 
{M(CO)3}+ core offers a number of attractive characteristics which include its small size that 
allows for labeling of low molecular weight biomolecules while maintaining its high activity and 
specificity.  In the specific case of 99mTc, this core allows technetium to be present in the +1 
oxidation state {Tc(I)} in a low spin d6 electronic configuration which can be used to prepare 
compounds that are inert, robust, and resistant to oxidation.  The fac-[M(CO)3(H2O)3]+ starting 
material is readily available in aqueous-based kit formulations and is soluble in water.  It has 
three aqua ligands that are readily exchangeable for substitution with the appropriate donor 
groups while the other face of the octahedron is ‘fixed’ due to the carbonyl ligands being inert to 
substitution.1,2,6,13,14  Figure 5.2 below shows a variety of tridentate ligands which are very 
effective in substituting the aqua ligands to provide chemically robust complexes. 
 
 
Figure 5.2 Tridentate ligands for chelation to the {M(CO)3}+ core.   
 
Figure 5.3 below shows the reductive alkylation of lysine or other amino acid derivatives 
for the preparation of homo- and hetero-dialkylated (mixed) derivatives of amino acids.15  
Chelating ligands incorporating amine, aromatic N-heterocycles, and carboxylate donors were 
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specifically chosen based on studies that determined nitrogen donors were the most effective 
ligands for the [M(CO)3]+ core.16 
 
 
Figure 5.3 Synthetic scheme for the preparation of homo- and hetero-dialkylated products.  
Reaction conditions: (i) R1CHO, DCE, NaBH(OAc)3; (ii) R1CHO, DCE; (iii) R2CHO, DCE, 
NaBH(OAc)3; (iv) DCE, NaBH(OAc)3. 
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5.2 Fluorescence Studies and Crystal Structure 
 As described before, {Re(CO)3}+ complexes are fluorescent and nitrogen donors are the 
most effective ligands for the {M(CO)3}+ core.  Figure 5.4 below shows the structures of 
different SAAC ligands that can bind to a metal center using the nitrogen donors in a tridentate 
fashion along with the {Re(CO)3}+ bound complexes that were obtained for preliminary 
fluorescence studies. 
 
 
Figure 5.4 Structures of SAAC ligands and {Re(CO)3}+ complexes. 
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Each sample was dissolved and diluted with methanol.  Table 5.1 below lists the 
concentrations of each sample.   
 
Sample Name Concentration (µM) Molar Extinction Coefficient (M-1cm-1) 
Boc-SAACB 59.0 1.1 x 104 
Boc-SAAC2B 65.6 7.0 x 103 
Boc-SAAC3 31.3 7.0 x 103 
Re-Boc-SAACB 37.5 1.3 x 104 
Re-Boc-SAAC2B 43.8 1.1 x 104 
Re-Boc-SAAC3 30.6 1.4 x 104 
 
Table 5.1 Concentrations of each sample and the calculated molar extinction coefficients 
based on the absorption spectrum. 
 
These concentrations were used in UV-Vis experiments to obtain an absorbance spectrum for 
each sample and the extinction coefficients were calculated (shown in Table 5.1) using the 
equation shown below in Figure 5.5.  The absorbance spectrum for each sample is shown at the 
end of the chapter in Figures A1-A6. 
 
A = ! !! !c 	  
Figure 5.5 Beer-Lambert Law.  A = absorbance; ! = length of light path (width of the 
cuvette); ε = molar extinction coefficient (molar absorptivity); c = concentration.  Units for 
absorbance – unitless; concentration – mol/L (M); length of light path – cm; molar extinction 
coefficient – molL-1cm-1 or M-1cm-1. 
 
The same samples used for the UV-Vis studies were used for the fluorescence studies as 
well.  Emission spectra were obtained from each of the six samples using a quartz cuvette.  Each 
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sample was excited at 295 nm but Re-Boc-SAAC2B (chosen at random) was excited at 265 nm, 
290 nm, 370 nm, 327 nm, 425 nm, and 450 nm.  These wavelengths were chosen based on 
previous work done on a similar {Re(CO)3}+ complex.17  Figures B1-B12 at the end of the 
chapter show the emission spectrum for each sample. 
 Most of the samples were originally in a powdered state but a few of them were in good 
crystalline quality.  These samples were run on the single crystal X-ray diffractometer.  The 
crystal chosen from the Boc-SAAC2B sample proved to be a decomposition product, sodium 
benzoate.  Figure 5.6 below shows the structure. 
 
 
Figure 5.6 Structure of sodium benzoate. 
 
Another sample, from Re-Boc-SAACB, was also a decomposition product, and in this case a 
polymorph of the amino acid aspartic acid.  Table 5.2 and Figure 5.7 below show the unit cell 
parameters and crystal structure of the amino acid. 
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Crystallographic Data 
Empirical formula C4H7NO4 
Formula weight (g/mol) 133.10 
Space group C2/c 
Crystal system Monoclinic 
a (Å) 17.604(4) 
b (Å) 7.337(14) 
c (Å) 9.1436(17) 
α (°) 90 
β (°) 116.501(6) 
γ (°) 90 
V (Å3) 1059.3(4) 
 
Table 5.2 Crystallographic data for the structure of aspartic acid. 
 
 
Figure 5.7 Crystal structure of aspartic acid. 
 
5.3 Synthesis of Novel Single Amino Acid Chelates 
 Extensive research has been done to optimize the preparation of amino acid based ligands 
attached to N,N; S,N; S,S donors.  In the meanwhile, whereas some research has been done on 
the complexing of the {Re(CO)3}+ core to N,N donor groups, very little has been done on the 
mixed N,S system or S,S donor groups.  Thiazoles were then selected as the ideal choice as they 
contain both a nitrogen and sulfur atom.  The aldehyde position can also be changed to easily 
study a variety of N,S and S,S systems. 
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 The first mixed system that was attempted was using 2-thiazolecarboxaldehyde (T2A) 
and 5-thiazolecarboxaldehyde (T5A).  The second mixed system was attempted using 4-
thiazolecarboxaldehyde (T4A) and 5-thiazolecarboxaldehyde (T5A).  Figure 5.8 below shows 
the reaction scheme for the synthesis using N-boc-1,4-butanediamine as the amino acid 
deriviative. 
 
 
Figure 5.8 Reaction scheme of SAAC ligands: (1) T2A and T5A; (2) T4A and T5A.  
Reaction conditions: (i) DCE, NaBH(OAc)3. 
 
During the synthesis, one complication that emerged was the low yield of the final product.  
Many different references confirmed yields as high as 90% using the same methods.  To try and 
achieve maximum yield, new materials were purchased and reactions were carried out as 
carefully and as precise as possible.  Purification using high performance liquid chromatography 
(HPLC) was not possible, so column chromatography was utilized.  Once the compound was 
thought to be pure, crystallization was attempted but proved to be unfruitful. 
 The mixed ligand system using the thiazole derivatives served as practice for future 
reactions that were attempted.  2-quinolinecarboxaldehyde (Q2A) was substituted in for the 
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thiazoles and a homo-di-substituted system was decided upon rather than a mixed system.  
Figure 5.9 below shows the reaction scheme between N-Boc-1,4-butanediamine and Q2A.  Many 
attempts to achieve high yield and purity were met with failure; therefore, it was decided to take 
the synthesis apart and take it one step at a time. 
 
 
Figure 5.9 Reaction scheme of N-Boc-1,4-butanediamine with Q2A to yield NBoc-Q.  
Reaction conditions: (i) DCE, NaBH(OAc)3. 
 
 The original synthesis calls for a direct double alkylation from a primary amine to a 
tertiary amine using NaBH(OAc)3 as the reducing agent in a one pot synthesis.  The decision to 
keep the same reducing agent and solvent but alter the steps of the synthesis was determined to 
be the best choice in taking a closer look at the chemistry being carried out.  Instead of two 
equivalents of Q2A with reducing agent in one pot, only one equivalent was used without 
reducing agent to form the mono-substituted imine.  Then reducing agent was added to form the 
secondary amine.  These two steps achieved almost optimal yield.  The addition of another 
equivalent of Q2A proved to be problematic possibly due to steric hindrance of the secondary 
amine. 
 Once the reaction conditions were optimized, other linkers/tethers were purchased 
including a lysine derivative and ethanolamine (ETA).  Figure 5.10 below shows the reaction 
schemes using the different linkers. 
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Figure 5.10 Reaction scheme of (1) N-α-Fmoc-L-lysine with Q2A to yield lysine-Q; (2) 
ethanolamine (ETA) with Q2A to yield ETA-Q.  Reaction conditions: (i) DCE, NaBH(OAc)3. 
 
 5.3.1 SAACQ-Zn 
 Rather than chelate the ligands to a {Re(CO)3}+ core, other metals were used to 
determine if fluorescence occurred.  Figure 5.11 below shows the reactions of the ligand with 
metal.  In a random fashion, zinc(II) was paired with NBoc-Q, gallium(III) was paired with 
ETA-Q, and copper(II) was paired with lysine-Q.  Slow diffusion crystallization was conducted 
on all three compounds with SAACQ-Zn resulting in crystals.  The crystals were sent to the 
European Molecular Biology Laboratory (EMBL) in Grenoble, France and the structure was 
solved.  The other two compounds were a powder and did not survive the trip overseas. 
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Figure 5.11 Reaction scheme for chelating the metal to each ligand:  (1) NBoc-Q + zinc 
acetate = SAACQ-Zn; (2)  ETA-Q + gallium nitrate = ETAQ-Ga; (3) lysine-Q + copper acetate 
= lysineQ-Cu.  Reaction conditions: (ii) MeOH, 60 °C, 3 to 5 hours. 
 
 Table 5.3 below summarizes the crystallographic data for the SAACQ-Zn structure.  
Figure 5.12 below incorporates a diethyl ether molecule that was used to induce crystallization.  
Figure 5.13 below shows the crystal structure of the SAACQ-Zn complex.   
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Table 5.3 Crystallographic data for SAACQ-Zn. 
 
 
Figure 5.12 Crystal structure of SAACQ-Zn with diethyl ether.  Hydrogen atoms have been 
omitted for clarity.  Color scheme: Zn – teal; carbon – white; nitrogen – blue; oxygen – red; 
chlorine – green. 
 
 
Crystallographic Data 
Empirical formula C33H44Cl2N4O3Zn 
Formula weight (g/mol) 340.49 
Crystal system Orthorhombic 
Space group P212121 
a (Å) 9.5300(19) 
b (Å) 14.580(3) 
c (Å) 24.220(5) 
α (°) 90 
β (°) 90 
γ (°) 90 
V (Å3) 3365.3(12) 
Z 4 
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Figure 5.13 Crystal structure of SAACQ-Zn.  Hydrogen atoms have been omitted for clarity.  
Color scheme: Zn – teal; carbon – white; nitrogen – blue; oxygen – red; chlorine – green. 
 
5.4 Summary and Conclusions 
 The crystallographic data obtained from the Re(I) complexes show obvious 
decomposition yielding in sodium benzoate and aspartic acid.  This resulted in less than 
interesting data gathered from the UV-Vis and fluorescence studies conducted. 
 Despite running into a lot of complications, the crystallization of a novel SAACQ-Zn 
compound was successful. 
 
5.5 Methods and Materials 
All chemicals were purchased from Sigma-Aldrich and used without further purification. 
All reagents were weighed in air and the reactions were conducted under an atmosphere of air, 
unless otherwise noted. 
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N-α-Fmoc-L-lysine was purchased from Advanced ChemTech (Louisville, KY). 
Water was distilled above 3.0 MΩ in-house using a Barnstead™ Model 525 Biopure Distilled 
Water Center from Thermo Scientific. 
Fluorescence experiments were performed using a Varian Cary® Eclipse Fluorimeter with 
permission from Mr. Mathew M. Maye at Syracuse University, Syracuse NY. 
UV-Vis experiments were performed using a Varian Cary® 50 UV-Vis Spectrometer. 
Flash column chromatography was done with silica gel 60 (240-400 mesh). 
Analytical TLC was performed using Merck glass-backed 0.2 mm silica gel 60 F-254 plates and 
visualized by ultra-violet light, I2, 1% ninhydrin in EtOH. 
1H NMR spectra were recorded on a Bruker ADVANCE™ III HD 400 MHz spectrometer. 
Crystallographic data was solved by Dr. Jon Zubieta and Dr. Chloe Zubieta at the European 
Molecular Biology Laboratory (EMBL) in Grenoble, France. 
 
 5.5.1 Synthesis of Novel Single Amino Acid Chelates 
 Imine Product 
 Amino acid derivative (N-Boc-1,4-butanediamine – 0.310 mL, 1.5 mmol; N-α-Fmoc-L-
lysine – 0.553 g, 1.5 mmol; ethanolamine – 0.090 mL, 1.5 mmol) was mixed with the aldehyde 
(2-quinolinecarboxaldehyde – 0.236 g, 1.5 mmol; 2-pyridinecarboxaldehyde – 0.143 g, 1.5 
mmol; 2-thiazolecarboxaldehyde – 0.132 g, 1.5 mmol; 4-thiazolecarboxaldehyde – 0.127 g, 1.5 
mmol; 5-thiazolecarboxaldehyde – 0.130 g, 1.5 mmol) in a 1:1 equivalence under a N2 or argon 
atmosphere for 30 minutes at room temperature in DCE (10 mL).  Isolated product produced the 
formation of an imine bond with mono-substitution. 
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 Secondary Amine Product 
 Once the mono-substitution with an imine bond was formed, ~1 equivalence of 
NaBH(OAc)3 (0.318 g, 1.5 mmol) was added and allowed to stir overnight at room temperature 
to reduce the imine bond to a secondary amine. 
 
 Mixed (Hetero) Dialkylated Product 
 Amino acid derivative (N-Boc-1,4-butanediamine – 0.310 g, 1.5 mmol) was mixed with 
aldehyde (2-thiazolecarboxaldehyde – 0.132 g, 1.5 mmol; 5-thiazolecarboxaldehyde – 0.130 g, 
1.5 mmol) in a 1:1 equivalence under a N2 or argon atmosphere for 30 minutes at room 
temperature in DCE (10 mL).  Subsequently, NaBH(OAc)3 (0.318 g, 1.5 mmol) along with the 
second aldehyde (4-thiazolecarboxaldehyde – 0.127 g, 1.5 mmol; 5-thiazolecarboxaldehyde – 
0.130 g, 1.5 mmol) was added and allowed to stir overnight at room temperature.  The reaction 
mixture was diluted with CHCl3 (10 mL) and decomposed with H2O (20 mL).  The organic layer 
was washed with a brine solution (10 mL x2), dried over Na2SO4, and concentrated under 
vacuum.  The residue was purified by column chromatography using MeOH:CHCl3 (1:6) as the 
eluent and fractions were collected which were subject to TLC.  Fractions containing product 
were concentrated under vacuum. 
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 Homo Dialkylated Product 
 Amino acid derivative (N-Boc-1,4-butanediamine – 3.10 mL, 1.5 mmol; N-α-Fmoc-L-
lysine – 0.553 g, 1.5 mmol; ethanolamine – 0.090 mL, 1.5 mmol) was mixed with aldehyde (2-
quinolinecarboxaldehyde – 0.472 g, 3.0 mmol; 2-pyridinecarboxaldehyde – 0.286 mL, 3.0 
mmol) in a 1:2 (AA:CHO) equivalence under a N2 or argon atmosphere for 30 minutes at room 
temperature in DCE.  Subsequently, ~2 equivalence of NaBH(OAc)3 (0.636 g, 3.0 mmol) was 
added and allowed to stir overnight at room temperature.  The reaction mixture was diluted with 
CHCl3 (10 mL) and decomposed with H2O (20 mL).  The organic layer was washed with a brine 
solution (10 mL x2), dried over Na2SO4, and concentrated under vacuum.  The residue was 
purified by column chromatography using MeOH:CHCl3 (1:6) as the eluent and fractions were 
collected which were subject to TLC.  Fractions containing product were concentrated under 
vacuum.  Figure 5.14 below shows the reaction synthesis for the various products using 
Na(OAC)3 as a reducing agent. 
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Figure 5.14 Reaction scheme for the synthesis of homo- and hetero-dialkylated products.  
Reaction conditions: (i) X1NH2, R1CHO, DCE, NaBH(OAc)3; (ii) X1NH2, R1CHO, DCE; (iii) 
X1NH2, R2CHO, DCE, NaBH(OAc)3; (iv) X1NH2, DCE, NaBH(OAc)3.  (1) N-α-Fmoc-L-lysine; 
(2) N-Boc-1,4-butanediamine; (3) ethanolamine; (4) 2-thiazolecarboxaldehyde; (5) 5-
thiazolecarboxaldehyde; (6) 4-thiazolecarboxaldehyde; (7) 2-pyridinecarboxaldehyde; (8) 2-
quinolinecarboxaldehyde. 
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 Complexing Metal to Ligand 
 Ligand (NBoc-Q – 0.0458 g, 0.1 mM; ETA-Q – 0.0343 g, 0.1 mM; lysine-Q – 0.0650 g, 
0.1 mM) and metal (zinc acetate – 0.0220 g, 0.1 mM; gallium nitrate – 0.0256 g, 0.1 mM; copper 
acetate – 0.0200 g, 0.1 mM) were dissolved in a 1:1 equivalence in MeOH and refluxed at 60 °C 
for 3 to 5 hours.  The residue was concentrated under vacuum and dissolved in the appropriate 
solvents for crystallization.  Figure 5.15 below shows the reaction between the metal and ligand. 
 
 
Figure 5.15 Reaction scheme for complexing metal to ligand.  Reaction conditions: (i) MeOH, 
60 °C, 3 to 5 hours. 
 
5.6 Appendix 
 
Figure A1 Absorbance spectrum of Boc-SAACB. 
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Figure A2 Absorbance spectrum of Boc-SAAC2B. 
 
 
Figure A3 Absorbance spectrum of Boc-SAAC3. 
 
	   132 
 
Figure A4 Absorbance spectrum of Re-Boc-SAACB. 
 
 
Figure A5 Absorbance spectrum of Re-Boc-SAAC2B. 
 
	   133 
 
Figure A6 Absorbance spectrum of Re-Boc-SAAC3. 
 
 
Figure B1 Emission spectrum of Boc-SAACB at excitation wavelength 295 nm. 
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Figure B2 Emission spectrum of Boc-SAAC2B at excitation wavelength 295 nm. 
 
 
Figure B3 Emission spectrum of Boc-SAAC3 at excitation wavelength 295 nm. 
 
 
Figure B4 Emission spectrum of Re-Boc-SAACB at excitation wavelength 295 nm. 
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Figure B5 Emission spectrum of Re-Boc-SAAC2B at excitation wavelength 295 nm. 
 
 
Figure B6 Emission spectrum of Re-Boc-SAAC3 at excitation wavelength 295 nm. 
 
 
Figure B7 Emission spectrum of Re-Boc-SAAC2B at excitation wavelength 265 nm. 
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Figure B8 Emission spectrum of Re-Boc-SAAC2B at excitation wavelength 290 nm. 
 
 
Figure B9 Emission spectrum of Re-Boc-SAAC2B at excitation wavelength 327 nm. 
 
 
Figure B10 Emission spectrum of Re-Boc-SAAC2B at excitation wavelength 370 nm. 
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Figure B11 Emission spectrum of Re-Boc-SAAC2B at excitation wavelength 425 nm. 
 
 
Figure B12 Emission spectrum of Re-Boc-SAAC2B at excitation wavelength 450 nm. 
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Chapter 6. Ongoing and Future Work 
 
6.1 Crystal Structure of a CitMHS Protein 
 The knowledge of CitMHS proteins remains largely unknown, both on a fundamental 
level and on a more specific level, due to the difficult nature of purification.  Purification of these 
proteins along with crystal structures can lead to important information that can aid in the 
production of antibodies and vaccines. 
 Different purification tags (i. e. peptide tags such as HIS or FLAG tags) can be studied to 
determine the effectiveness of the purification.  With successful protein purification, the proteins 
can be screened for use in various antibody development and subsequent animal studies.  In 
addition to antibody and vaccine development, detection methods can be utilized to help 
hospitals and military personal combat pathogenic infections and diseases such as anthrax and 
MRSA putatively caused by CitBa and CitmrSa, respectively. 
 Crystal structures, not only of CitBa and CitmrSa but other CitMHS proteins belonging to 
different native host organisms, can lead to important information regarding metal-citrate 
transport.  Structures could lead to insights on the pore size of different CitMHS members 
depending on which metal-citrates are transported.   The placement of each amino acid residue 
can aid in determining which residues participate in binding and transport.  If a structure with an 
intact metal-citrate complex bound to the protein is obtained, the following can be identified: the 
precise location of specific amino acids that contribute to binding and transport; the shape of the 
protein with and without the bound complex; the relationship between the protein pore size and 
size of metal ions transported; and the relationship between coordination geometry and 
selectivity of complexes transported.  
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6.2 Radiation Studies for Metal-Citrate Uptake 
 To date, only a few organisms with CitMHS members have been fully characterized.  
Finding other organisms that are believed to possess CitMHS members and performing radio 
flux assays to determine what metal-citrate complexes are transported will help further current 
knowledge about this specific family of proteins. 
 Radio flux assays can be performed on the native host itself or by cloning the gene into 
other hosts.  All previous radio flux assays were completed with a 1:1 metal to ligand ratio.  
Increasing this ratio to 1:2 or even 1:3 (metal:ligand) might form species in solution different 
from those formed by the 1:1 ratio.  This might change the metal-citrate recognition to allow for 
the transport and uptake of the complex. 
 Creating a library of information based on metal-citrate complexes transported, 
performed by radio flux assays coupled with information obtained from crystal structures of 
proteins and complexes (i.e. which amino acids participate in binding, how pore size affects what 
metals are transported), will help with the advancement of this field.  A lot remains to be done 
which can result in a vast array of research applications. 
 
6.3 Crystal Structures of Metal-Citrate Complexes 
 While there exists quite an extensive library on metal-citrate complexes ranging from 
simple to complex structures, there still remains a separation of knowledge between solid-state 
chemistry and microbiology.  As more structures are obtained, more knowledge is gained 
regarding how specific metals bind to the citrate ligand under certain environments and 
conditions.  Currently there is a lack of metal-citrate crystal structures produced under pseudo-
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physiological conditions.  These structures would help in understanding the binding and 
coordination of metal-citrate complexes within biological organisms. 
 Some of the previously completed reactions, which failed to yield positive results, could 
be revisited. Instead of using slow evaporation, different techniques such as slow diffusion in a 
test tube could yield in better results.  Similarly, H-tubes can be utilized to achieve slow 
diffusion crystallization.  Most of the reactions were performed at room temperature but applying 
heat to increase solubility might also produce better results due to the slow cooling of the 
solvent.  This might lead to the formation of smaller crystals that are better in quality.  Citrate is 
an effective solubilizing agent, which results in crystallization that can prove to be difficult.  All 
the methods and techniques suggested are ways to combat the effectiveness of citrates ability to 
keep complexes in solution. 
 Comparing solid-state crystals and species in solution could give insight into how metal-
citrate complexes act within organisms as opposed to solid-state trends that are biologically 
irrelevant.  To supplement these crystal structures, ESI-MS can be used on solutions that yield 
crystals in order to obtain information on which species exist in solution.  These species studies 
can also aid in radio flux assays so that a direct correlation between solid-state and biological 
uptake/transport can be made.  All of this information can immensely help in potentially bridging 
the gap between the inorganic and organic. 
 
6.4 Single Amino Acid Chelates 
 In keeping up with an increasingly health-conscious society, science and technology are 
constantly evolving and innovating to support the development of medical advancement.  There 
is an abundance of different combinations of joining together amino acid derivatives with donor 
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groups to make an effective SAAC.  Synthesis and fluorescence studies of these SAAC’s can 
help create a more extensive and elaborate library that can help organize the plethora of 
compounds that currently exists. 
 The reaction using Q2A and N-Boc-1,4-butanediamine has been optimized so that future 
synthesis can be performed with little to no complications.  Previously, these reactions were 
executed on a small scale but future work could scale these up to obtain multi-gram quantities.  
In addition to Q2A and N-Boc-1,4-butanediamine, other systems could be studied such as 
pyridines, pyrimidines, imidazoles, and pyridazines along with the N-α-Fmoc-L-lysine and 
ethanolamine linkers.  Now that the crystal structure of SAACQ-Zn has been successfully 
obtained, more should be created in larger quantities so that fluorescence studies can be 
performed. 
 Fluorescence studies can determine which SAAC’s are optimal and used under specific 
conditions or if certain SAAC’s are completely obsolete.  With most of the attention being 
focused on metals such as technetium, rhenium, indium, iodine, and gallium for nuclear 
medicine, the potential of other metals go unnoticed.  Other metals that may have the potential 
for applications such as copper, ruthenium, zinc, and manganese can be investigated.  Different 
metal salts (i. e. nitrate, acetate, chloride, bromide, etc) should be explored by complexing them 
to the SAACs and performing fluorescence studies. 
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